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 MOLECULAR ASSOCIATIONS OF REPRODUCTIVE FAILURE 
Dara S. Berger, Ph.D. 
University of Pittsburgh, 2006
 
Approximately one in four pregnant women experience one or more miscarriages, making 
spontaneous abortion the most common pregnancy complication, and of public health 
importance. Recurrent spontaneous abortion (RSA) can be defined as the loss of two or more 
pregnancies and affects 1% of couples. This prevalence is higher than expected by chance, 
suggesting some couples have an underlying systemic cause for RSA.  
 
We have chosen to study two immunological aspects of pregnancy loss. The first 
involves maternal defense against infection in terms of predicted mannose binding lectin (MBL) 
plasma levels. The second approach is to analyze the human leukocyte antigen-G (HLA-G) gene, 
which is believed to play a role in maternal recognition of paternal antigens at the maternal-fetal 
interface.  
 
The case population included women having two or more clinically recognized 
spontaneous abortions as well as having unknown etiology for RSA. Control subjects were 
selected from healthy primiparous women with no history of miscarriage. Cases and controls 
were genotyped for five MBL single nucleotide polymorphisms (SNPs). Both populations 
genotyped were in Hardy-Weinberg equilibrium, at all five sites. Fisher’s exact test of cases and 
controls was not significant at each of the five sites, p-values > 0.05. No association was 
observed between MBL genotypes or predicted MBL plasma levels and risk of RSA, or presence 
of live birth and recurrent pregnancy loss, among women with unexplained RSA.  
 
Using the same population, the HLA-G promoter region and 3’ untranslated region 
(UTR) was sequenced in cases and controls. Twenty-three SNPs were observed with a minor 
allele frequency >0.02 in the promoter region. Linkage disequilibrium was detected throughout 
1400 base pairs of the promoter region that were sequenced. While SNP data revealed allele 
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frequency differences between cases and controls, haplotype data proved even more beneficial; 
one haplotype potentially predicting increased risk of RSA, while the other potentially protecting 
against risk of RSA. Finally, cases had a higher frequency of individuals homozygous for the 14 
base pair insertion in the 3’ UTR. 
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1.0  INTRODUCTION: SPONTANEOUS ABORTION 
Reproductive failure is a broad term meaning the inability to conceive, known as infertility, or 
the inability to maintain a pregnancy, known as miscarriage (Wold and Arici 2005). A 
miscarriage is any loss before 20 gestational weeks (Devi Wold et al. 2005). Miscarriages affect 
15% of women, primarily in the first trimester, recurrent pregnancy loss occurs in one to two 
percent of this population (Clark et al. 2001). Most recurrent abortions involve a number of 
consecutive losses, three or more.  Recurrent spontaneous abortion (RSA) has also been defined 
as two or more spontaneous abortions (Lanasa and Hogge 2000). Patients with a single live birth 
followed by a series of miscarriages are considered to have similar conditions to those with only 
miscarriages (Clark et al. 2001). A genetic component may be involved when a woman 
experiences a mixture of live births and miscarriages (Clark et al. 2001).  
 
Determining a cause for miscarriage has become the topic of many studies. In couples 
experiencing repetitive pregnancy loss, approximately two-thirds can establish a definite cause 
after thorough evaluation, i.e. genetic endocrinologic, anatomic, immunologic, thrombophilic 
and physician assessment (Stephenson 1996). Women with two losses have identifiable problems 
just as frequently as women with three or more losses (Devi Wold et al. 2005), therefore it is 
reasonable to group both populations together in research and clinical situations. 
 
Lack of success of previous pregnancies is a risk factor affecting incidence of miscarriage 
in women; reproductive history is important for couples trying to have children. Women with no 
live births experiencing repeated pregnancy loss are known as primary recurrent spontaneous 
aborters, while women with previous live births experiencing spontaneous abortions are 
classified as secondary recurrent spontaneous aborters.  Primary recurrent aborters have a rate of 
miscarriage as low as five percent that increases to 50% after three or more losses (Dhont 2003). 
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The risk of a fourth loss is 30% in secondary recurrent aborters with three or more losses (Dhont 
2003).  
 
Known causes of recurrent miscarriages include genetic factors, environmental 
influences, infection, metabolic and endocrine effects as well as anatomic defects. 
Approximately 20-50% of recurrent miscarriages however have unknown etiologies (Laird et al. 
2003). Because of the multi-factorial nature, recurrent spontaneous abortion is difficult to 
diagnose and treat. Maternal and fetal immune response is an important but understudied area 
that has been suggested to provide answers for unknown spontaneous abortions.  
 
It is extremely likely that more than one immune cause for recurrent miscarriage exists. 
There are two theories linking pregnancy loss to immune factors. The first idea involves 
maternal and fetal defense against infection. If the mother is exposed to pathogens, the body’s 
method of resistance to microorganisms could also harm the pregnancy. Furthermore, because 
the fetus has an immature immune system, introduction of infection could directly harm the 
fetus, resulting in termination. The second theory involves maternal immune system recognition 
of paternal antigens on the feto-placental unit, followed by damage to fetal cells and abortion 
(Laird et al. 2003). The mechanisms that protect a pregnancy from the maternal immune system 
are not well understood therefore immunological assessment of normal pregnancy, let alone 
abnormal pregnancy, is challenging (Laird et al. 2003).  
 
We plan to test both theories by looking at two different genes responsible for immune 
responses. Mannose binding lectin (MBL) may be responsible for opsonization of pathogens and 
activated by maternal response to infection while human leukocyte antigen-G (HLA-G) may be a 
factor in paternal antigen recognition by mother and/or the fetus.  
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2.0  RESEARCH 
2.1 HYPOTHESIS 
Multi-site haplotypes in the MBL gene and in the promoter region of HLA-G are associated with 
increased genetic risks of recurrent pregnancy loss.  
2.2 OBJECTIVES 
2.2.1 Specific aim one 
Several infectious agents have been proposed as a cause for recurrent miscarriage and preterm 
labor. The first specific aim is to genotype mis-sense mutations related to reduced MBL, as well 
as MBL promoter region polymorphisms, associated with altered MBL expression. We will 
classify our cases and controls by high, intermediate and low MBL levels based on the mis-sense 
mutations and promoter polymorphisms to see if there is a relationship between certain MBL 
alleles and predicted quantitative MBL levels in case and control populations. 
2.2.2 Specific aim two 
The HLA-G gene is primarily expressed by trophoblast cells, which are in contact with mother 
and fetus. The second specific aim is to sequence 1400 base pairs in the HLA-G promoter region 
in order to study the polymorphisms and haplotypes. With an abundance of literature concerning 
the HLA-G gene and only a few groups investigating the promoter region, there is a large 
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amount to be learned concerning the gene’s structure and function in respect to recurrent 
pregnancy loss. 
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3.0  BACKGROUND 
3.1 MANNOSE BINDING LECTIN 
 
3.1.1 Innate immune system 
The innate immune system is the principal defense against infection if/when the adaptive 
immune response is either compromised or too immature to react. Mannose binding lectin 
(MBL), also known as mannan binding lectin, is produced by the liver and travels though blood. 
MBL is a calcium dependant lectin and a component of the innate immune system. More 
specifically, MBL is a collectin, which is a C-type lectin that plays a role in the immune response 
against invading organisms (Bernig et al. 2004; Holmskov et al. 2003). MBL is one of five 
collectins, the remaining four being the pulmonary surfactant proteins SP-A and SP-D, and the 
plasma lectins, conglutinin and CL-43.  
 
Collectins have a collagen-like region and a lectin region, each with an identifiable 
purpose. The collagen portion interacts with the effector elements of the innate immune 
response, while the lectin, or protein, region binds to sugar molecules on the surface of the 
pathogen (Mohr 2006). MBL, as well as the other collectins, function by binding to carbohydrate 
structures on the surface of microorganisms and foreign particles including bacteria, fungi, 
viruses and parasites (Eisen and Minchinton 2003). The interaction of the C-type lectin domain 
and the microbial carbohydrates leads to activation of the lectin complement system (Bernig et 
al. 2004; Eisen and Minchinton 2003; Holmskov et al. 2003).   
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The complement system consists of three pathways: the classical pathway, the alternative 
pathway and the lectin pathway. Together they are responsible for fighting infection via 
recruiting inflammatory cells, opsonization and eradicating pathogens (Figure 1) (Janeway 
2005). 
 
QuickTime™ and a
TIFF (Uncompressed) decompressor
are needed to see this picture.
 
Figure 1: Complement system pathways  
 
The lectin pathway is mediated by MBL (Kaiser 2006). A set of plasma proteins designed to 
respond to extracellular antigens circulate in the blood in inactive forms until they recognize 
foreign microorganisms, at which time they become active (Kaiser 2006). Because pathogens 
have different surface structures (i.e. mannose groups) they can be differentiated by MBL from 
mammalian cells. The lectin pathway is initiated by the binding of MBL to the mannose groups 
of microbial carbohydrates, resulting in chemotactical attraction of phagocytes, inflammation, B-
lymphocyte activation, etc. (Kaiser 2006). This response is part of an individual’s protection 
against disease.   
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3.1.2 Mannose binding lectin gene 
Circulating levels of MBL and functional activity are partially regulated by genetic variation in 
the MBL2 gene, which encodes for MBL (Bernig et al. 2004). The MBL2 gene is located on 
chromosome 10q11.2-21 and consists of four exons. An MBL pseudo-gene, MBL1, has been 
located in the same chromosomal region (Garred et al. 2003). Three different variant alleles in 
MBL2 coding for structurally abnormal proteins have been identified in codons 52, 54 and 57 of 
exon 1, also known as B, C and D alleles. In the proximal promoter region there are two other 
single nucleotide polymorphisms (SNPs), located at –550 and –221 or L/H and X/Y. Together, 
these SNPs can be used to form haplotypes, which have been reported to partially explain 
changes in complement activation and decreased circulating levels of MBL (Bernig et al. 2004).  
 
Individuals heterozygous for codon 52, 54 and 57 SNPs are susceptible to certain 
infections, due to low concentration levels of MBL, while concurrently protected against 
particular pathogens, specifically intracellular microorganism that depend on the MBL system 
for phagocytosis (Bernig et al. 2004). These structural variants have a significant reduction effect 
on serum MBL levels, more so than the promoter variants (Baxter et al. 2001). Ninety percent of 
individuals who are homozygous for the wild type structural gene have MBL concentratiosn >0.6 
µg/ml, while the majority of heterozygotes have plasma MBL levels <0.6 µg/ml (Baxter et al. 
2001; Madsen et al. 1994). Individuals who are homozygous or compound heterozygous for the 
less common alleles have MBL plasma concentrations of <1% of the wild type concentrations 
(Baxter et al. 2001). And heterozygotes have MBL plasma concentrations of about 10% of the 
wild type levels (Baxter et al. 2001).    
 
Most individuals who are MBL deficient do not get infections. One theory suggests a 
second immune defect must occur for susceptibility of infection to become pronounced 
(Summerfield 2003). Diseases such as bacterial infections (i.e. meningococcal disease), parasitic 
infection (i.e. malaria), cystic fibrosis and systemic lupus erythematosus have been associated 
with certain haplotypes and low serum MBL levels (Summerfield 2003). Furthermore, infection 
due to immunodeficiency (i.e. common variable immunodeficiency and bone-marrow 
transplantation) and vascular disorders are more common in those with low plasma MBL levels 
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(Tsutsumi et al. 2005). However, in some situations low MBL production can protect against 
disease. An MBL deficiency decreases the “infectivity” of some intracellular pathogens by 
limiting opsonization and phagocytosis (Worthley et al. 2005). Individuals with a significantly 
higher MBL levels than controls show resistance to Mycobacterium leprae (leprosy) as well as 
tuberculosis meningitis (Turner and Hamvas 2000; Worthley et al. 2005). 
3.1.3 Mannose binding lectin and pregnancy 
Reduced MBL levels in the mother and/or the fetus can have a negative effect on pregnancy. 
MBL deficient fetuses are more susceptible to infection and or inflammatory events in utero 
(Kilpatrick et al. 1999). This is because the fetus is less reactive to infection and therefore unable 
to properly activate the complement cascade and phagocytosis. If an infection is not detected 
early and/or is too severe, the fetus will not be able to adequately manage the pathogen and 
abortion may occur. 
 
Infection is also a concern for a pregnant mother with low MBL levels. A less sensitive 
innate immune response indicates the mother will be more susceptible to a prolonged and 
sustained inflammatory response. The consequence is a down-regulation of insulin sensitivity in 
response to the sustained release of inflammatory cytokines. This has the potential to contribute 
to gestational diabetes. Insufficient amounts of MBL have been linked to gestational diabetes 
mellitus, preterm birth and recurrent infection, all of which increase risk for RSA (Annells et al. 
2004; Megia et al. 2004).   
 
Furthermore if the fetus is exposed to more viruses, bacteria and disease as a result of the 
mother’s poor ability to fight infection adequately, pregnancy complications become more likely. 
Low maternal MBL levels can cause excess inflammatory responses and can harm the fetus 
directly by altering the fetus’s environment. The involvement of MBL deficiency with acute 
infantile infection suggests that a lack of sufficient MBL may lead to miscarriage (Baxter et al. 
2001; Madsen et al. 1994).   
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3.1.4 Mannose binding lectin literature review 
A 1999 study was performed with 146 Danish women and 46 Scottish women experiencing 
recurrent miscarriage. MBL levels were determined by serum or plasma assays, blood was drawn 
when patients were not pregnant. MBL levels were also investigated in 444 controls taken from 
males and females. Results showed a correlation between the frequency of MBL deficiency and 
number of miscarriages, p <0.01 (Christiansen et al. 1999).  
 
Another study found MBL concentrations less than or equal to 0.1 µg/ml were clinically 
significant to risk of miscarriage (Kilpatrick et al. 1999). By studying levels in 397 males and 
females experiencing RSA and 376 controls, it was confirmed that low MBL concentrations are 
over-represented in couples with RSA. The authors concluded the fetus’s MBL genotype is a 
critical factor in successful pregnancy and women with MBL less than or equal to 0.01 µg/ml are 
twice as likely to experience miscarriage as women with median levels of MBL (Kilpatrick et al. 
1999). 
 
In 2000, Kilpatrick conducted a study of MBL concentration during normal pregnancy. 
Using 14 patients, measurements of MBL were taken before and during pregnancy. Three 
patients experienced significant increases in MBL concentrations, however “significant increase” 
was not well defined. Conclusions were that a modest but significant increase occurs as a result 
of pregnancy, however it was also noted that MBL levels rarely increase during the first trimester 
but increase later in pregnancy (Kilpatrick 2000).   
  
In a comprehensive study by Baxter et al. 2001, the authors looked at the frequency of 
variants in MBL, tumour necrosis factor (TNF) and lymphotoxin alpha (LTA). Alleles in 76 
Caucasian couples experiencing RSA were examined. MBL variant frequencies associated with 
susceptibility to infection showed similar haplotype frequencies in cases and controls. Haplotype 
variation in TNF and LTA, which are associated with severity of infection, were also similar in 
cases and controls (Baxter et al. 2001).  
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More data was generated when pregnancy success and MBL serum levels were compared 
in 217 women experiencing RSA and 111 of their husbands. Controls were 104 couples with no 
history of reproductive complications and 210 blood donors. Blood was taken from patients 
while they were not pregnant. Women experiencing RSA had insignificantly higher rates of 
MBL levels, less than or equal to 0.1 µg/ml (Kruse et al. 2002). Patients with MBL levels less 
than or equal to 0.1 µg/ml did show an increase in abortion rate than patients with normal MBL 
levels (Kruse et al. 2002). 
 
Finally of interest, a study was conducted in order to determine whether MBL interacts 
with Candida spp., yeast cells that cause valvovaginal candidiasis (Pellis et al. 2005), one of the 
most frequent vaginal infections. MBL, along with C1q and C3, are the molecules of the 
complement system therefore they included all three candidates in the analysis. Cases included 
47 women experiencing gynecological symptoms of infection and 23 healthy women with no 
clinical signs of inflammations. Findings showed when there is vaginal infection MBL and C3 
are present in the vaginal cavity acting as recognition molecules for the infectious agents (Pellis 
et al. 2005). MBL, but not C1q, binds to bacteria and fungi in the vagina, suggesting a lectin 
pathway and a classical pathway play a role in immune defense (Pellis et al. 2005).  
 
In summary, it has been confirmed that MBL levels are a factor in pregnancy. It is also 
apparent that MBL plays a role in the defense against vaginal infection. MBL is essential to 
successful pregnancy in regards to maternal defense against infection. Yet there is still some 
debate as to significant differences in maternal MBL levels between cases and controls 
associated with pregnancy loss. MBL is involved in maternal immune function and therefore 
affects the vaginal cavity’s response to disease. Given that MBL has a role in maternal and fetal 
immune response and that disease potentially affects pregnancy, there is justification for further 
analysis of MBL and its association to RSA. 
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3.2 HUMAN LEUKOCYTE ANTIGEN-G 
3.2.1 Maternal fetal interface 
The placenta, a derivative of the trophoblast, makes up the maternal-fetal interface in all 
mammals (Agrawal and Pandey 2003). Trophoblst cells separate from the inner cell mass as the 
zygote, or fertilized egg, travel through the Fallopian tube prior to implantation in the uterine 
lining (Agrawal and Pandey 2003). These cells line the outside of the blastocyst, a hollow ball of 
cells approximately five to eight days old (Merck Manuals 2006). During implantation they bind 
to the endometrium and develop into two layers, an inner layer of mononuclear cytotrophoblasts 
and an outer layer of multinuclear cytoplasm (MedicalGlossary.org 2004). This outer layer forms 
the maternal-fetal interface, the placenta. The development and role of the placenta is important 
due to its physical connection of the genetically dissimilar embryo to the uterus.   
 
By definition a syncytuim is a large region of cytoplasm that contains many nuclei 
(Wikipedia 2006). The multinuclear cytoplasmic layer is also known as syncytiotrophoblasts, a 
mass of cytoplasm not separated into individual cells. The syncytiotrophoblast is a membrane 
directly exposed to maternal blood and all of the immune system agents circulating (Agrawal and 
Pandey 2003). This membrane surrounds the fetus and functions as a “biological dialysis 
membrane” involved in cooperative exchange of molecules into and out of the fetal environment 
(Agrawal and Pandey 2003). It is believed that the syncytiotrophoblast cells are responsible for 
the fetus’s immunological exemption from the mother’s immune system.  
 
Cytotrophoblasts, the inner layer of cells between the syncytiotrophoblast and chorionic villus 
capillaries, attach to the placenta and the maternal decidua (Wikipedia 2006). At the decidua, 
extravillous trophoblast (EVT) cells enter and natural killer (NK) cells become more proliferate 
(Moffett-King 2002). Extravillous trophoblast cells are the only trophoblast cells that express 
MHC class I antigens and interact with NK cells (Parham 2004). Human leukocyte antigen-G 
(HLA-G), a ligand for NK cell receptors, is expressed only by EVT and medullary epithelial 
cells (found in the thymus) whereas some of the other MHC class I molecules (i.e. HLA-C and 
HLA-E) are more common. 
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3.2.2 Natural killer cells 
NK cells are large granular lymphocytes. Their activity is regulated by the interaction of cell 
surface receptors with NK cell ligands expressed on the surface of pathogens. In contrast, 
interaction of an inhibitory receptor, such as killer cell immunoglobulin receptors (KIRs), with 
its ligand, negatively controls NK cell activity. NK cells are not classified as T cells or B cells 
however they do express cell surface antigens CD16 and CD56. NK cell function includes direct 
elimination of virus infected cells and the production of cytokines, providing rapid but non-
specific response to infection (Wold and Arici 2005). NK cells recognize and lyse target cells by 
two mechanisms, antibody dependant cell cytotoxicity and natural cytotoxicity (Yamada et al. 
2005).  
 
A distinctive feature of the uterine mucosa during pregnancy is the presence of a large 
population of NK cells known at uterine natural killer cells (uNK). Uterine natural killer cells 
can be differentiated by their high expression of CD56, a neural cell adhesion molecule and NK 
cell marker, in comparison to peripheral blood NK cells (Wold and Arici 2005). In early 
pregnancy uNK cells comprise approximately 70% of the total leukocyte population in the 
decidua (Wold and Arici 2005). It is not until after 20 weeks of gestation that the population of 
uNK cells decreases (Moffett-King 2002).  
 
When pregnancy occurs, the uNK cells localize in the decidua coming into contact with the 
invading trophoblast (van der Meer et al. 2004). Their presence during implantation and the 
expression of HLA-G receptors suggest a critical role during implantation through interaction 
with HLA-G, which are expressed on the invading trophoblast (Figure 2) (Emmer et al. 2002; 
van der Meer et al. 2004).  
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Figure 2: Location of HLA-G expression (Carter 2000) 
 
The uNK cell resistance is the result of an interaction between HLA-G and KIRs (Khalil-Daher 
et al. 1999).  KIRs obstruct cytolytic functions of killer cells, in this case uNK cells, by specific 
interaction with major histocompatability complex (MHC) class I molecules (Cho et al. 1999), 
i.e. HLA-G. Consequently, a deletion or mutation of the HLA-G gene could lead to loss of fetus 
in early pregnancy (Rouas-Freiss et al. 1997). 
3.2.3 Human leukocyte antigen-G gene 
There are two groups of MHC HLA genes: classical HLA class Ia (HLA-A, -B and -C) and II 
(HLA-DR, -DQ and -DP) and non-classical HLA class Ib (HLA-E, -F and -G). Less variation 
has been reported in HLA Ib genes in contrast to the highly polymorphic HLA Ia genes (Hviid 
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2006). Both the HLA Ia and Ib genes are located in the same region on the short arm of 
chromosome 6. In particular, HLA-G is located on chromosome 6p22.1; it is 3363 base pairs 
long, of which 1842 base pairs make up its six exons. The promoter region and 3’ untranslated 
region (UTR) surrounding the gene are polymorphic and of interest in many spontaneous 
abortion studies. HLA-G is expressed in all EVT populations including the cytotrophoblast cells, 
interstitial trophoblasts, endovascular trophobalsts and placental cells (Agrawal and Pandey 
2003). Because of HLA-G’s proximity to fetal tissue, a genetically foreign entity, and its role in 
the maternal and fetal immune defense, it is likely that HLA-G expression and subsequent 
interaction with uNK cells and KIRs is a factor in all, successful and unsuccessful, pregnancy. 
3.2.4 Human leukocyte antigen-G literature review 
3.2.4.1 HLA-G exon 2 and exon 3 
In 2001 Pfeiffer et al. studied 78 Caucasian couples experiencing three or more RSA. The 
control population consisted of 52 Caucasian women with at least one successful pregnancy and 
no history of infertility. After sequencing exon 2 and exon 3, 14 different alleles were found in 
the cases and controls. Two HLA-G alleles, *01013 and *0105N, were more frequent in patients 
with RSA compared with fertile controls. These alleles are also associated with lower levels of 
circulating soluble HLA-G (Pfeiffer et al. 2001). The conclusion was HLA-G genotype may be a 
contributing risk factor in RSA.  
 
A different study suggested that HLA-G alleles *0104 and *0105N are associated with 
couples experiencing RSA (Aldrich et al. 2001). One hundred thirteen couples with unexplained 
RSA and no more than one live birth were genotyped for seven polymorphism defining twelve 
HLA-G alleles. Ethnicities included Caucasians, African-Americans, Hispanics, one East Asian 
and one Asian Indian. This study also supported the association between HLA-G*0105N Pfeiffer 
et al. reported. However, HLA-G allele *01013 was not associated with pregnancy loss in this 
study.   
 
Most recently, a study of 120 Indian women experiencing three or more consecutive 
miscarriages compared exon 2 and exon 3 polymorphisms to those in 120 fertile controls. Eleven 
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alleles were found and data supported their hypothesis that HLA-G polymorphism may 
contribute to recurrent fetal loss. In this study HLA-G alleles *010103, 010105 and 010108 were 
more frequent in women experiencing RSA (Abbas et al. 2004). 
 
3.2.4.2 HLA-G 3’ untranslated region 
The 3’ UTR of HLA-G, frequently referred to as exon 8 in the literature, was first investigated in 
1995 by K.E. Humphrey. Within the 3’UTR is a 14 base pair insertion/deletion that is associated 
with a splice variant resulting in a 92 base pair removal in the 3’ UTR upstream of the 3’UTR 
insertion/deletion. The 92 bp deletion is located at the beginning of “exon 8” and extends to the 
3’ UTR to a potential acceptor AG site (Rousseau et al. 2003).  
 
With this information, pedigrees and the 14 base pair deletion were analyzed via linkage 
analysis and genotyping (Humphrey et al. 1995). One hundred ninety-six individuals including 
pre-eclamptic/eclamptic (PE/E) pregnant women, individuals from PE/E pregnancies, relatives, 
husbands and controls were genotyped. Looking only at the 3’UTR they stated genotypic and 
gene frequencies were not significantly different in the groups studied and linkage between 
maternal expression of HLA-G and PE/E is unlikely (Humphrey et al. 1995).  
 
In 2003 placentas from normal and mild pre-eclampsia (PE) pregnancies were used to 
examine HLA-G’s possible role in pregnancy. Rousseau et al. analyzed the effect of the 14 base 
pair deletion on the stability of HLA-G mRNAs by performing actinomycin D treatments on 
JEG-3 choriocarcinoma cell lines and M8 melanoma cell lines transfected with HLA-G*010102 
allele. They found HLA-G mRNAs with the 92 base pair deletion are more stable than complete 
mRNA. Conclusions suggested this region to be involved in mechanisms for controlling post-
transcriptional regulation of HLA-G molecules associated with allelic variants (Rousseau et al. 
2003).  
 
This was further studied in a group of 90 women consisting of in vitro fertilization (IVF) 
patients and those experiencing RSA, as well as 93 controls. It was concluded that the 
homozygous individuals with the 14 base pair insertion in the 3’ UTR were significantly 
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associated with reduced fertility in respect to unsuccessful IVF treatments and increased risk of 
recurrent miscarriage (Hviid et al. 2004a). Also in 2004 Hviid published a paper looking at 
healthy and PE pregnancies in a Danish population. Associations between the 14 base pair 
deletion in the 3’ UTR were compared with birth weight, placental weight and placental ratio 
(Hviid 2004). A presence of the deletion was associated with increased birth weight in 
relationship to gestational age and with placental weight at birth. There was also a slightly higher 
placental ratio in the offspring homozygous for the 14 base pair insertion genotype (Hviid 2004). 
 
One of the largest studies of the insertion/deletion in the 3’ UTR included 120 women 
with no children, 110 had 3 or more RSA and 120 healthy women with three or more live births. 
Hardy-Weinberg equilibrium (HWE) showed no difference between homozygotes for the 
insertion/deletion in normal fertile women and RSA women. They did find a difference between 
heterozygotes in normal women and women with RSA. Frequency of heterozygotes was 
significantly increased in RSA women compared to normal fertile women (X2 =6.014, p <0.01) 
(Tripathi et al. 2004). The frequency of the 14 base pair deletion was 52% in fertile women and 
51.6% among women experiencing recurrent fetal losses with no known cause (Tripathi et al. 
2004). These results are contradictory to Hviid et al. 2002, whose group reported observing more 
heterozygotes in controls as compared to RSA cases. 
3.2.4.3  HLA-G exons and 3’ untranslated region 
A comprehensive HLA-G study was conducted in 1996 by Ober et al. Eighty individuals were 
randomly selected from a group of several hundred Hutterites, a population known to have 
naturally high fertility rates (Ober et al. 1996). Six HLA-G alleles were defined by exon 2, exon 
3 and the 3’ UTR variation. Low levels of variation in exon 2 and exon 3 were reported. In 
general, this study did not have a fertility or infertility focus however they showed Hutterites 
with polymorphisms did not experience deleterious affects on pregnancy outcomes (Ober et al. 
1996).  
 
Examining exons 2, 3, 4 and the 3’UTR, in 61 Danish couples experiencing 3 or more 
spontaneous abortions and 47 control couples, Hviid et al. reported a greater number of 
heterozygotes for the 14 base pair insertion/deletion polymorphism in controls than in cases. 
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HLA-G histo-incompatibility between the fetus and placental unit and the mother was not 
supported (Hviid et al. 2002). This was followed up in 2003 with a study of trophoplast biopsies 
from 12 Caucasian first trimester placentas from elective termination pregnancies. Primers in 
exon 2 and the 3’ UTR were used to generate products of HLA-G transcripts from a 
heterozygous sample (Hviid et al. 2003). A relationship between HLA-G polymorphisms and 
mRNA levels of different alternatively spliced HLA-G isoforms in first trimester trophoblast cell 
populations were reported (Hviid et al. 2003). However when the same group looked at placentas 
from 20 uncomplicated and PE pregnancies, no association between HLA-G protein expression 
and HLA-G genotype in placentas was found (Hviid et al. 2004b).  
 
Using a definition of RSA as three or more consecutive fetal deaths prior to 28 weeks 
gestation, Hviid and Christiansen looked at polymorphisms again in exons 2, 3, 4 and the 3’ 
UTR. The case population included 57 Danish women and 47 of their husbands, while the 
control population consisted of 44 couples. They reported strong linkage disequilibrium existing 
between HLA-GR3 (an HLA class II gene) locus and HLA-G* 010102 in RSA patients (Hviid 
and Christiansen 2005). 
3.2.4.4 HLA-G promoter region 
In 1999, Hviid et al. performed the first investigation of the HLA-G promoter region. Their goal 
was to detect any possible sequence variation that may affect transcription factor binding, 
possibly influencing the level or developmental regulation of HLA-G expression (Hviid et al. 
1999). Their study included ten DNA samples, consisting of two randomly selected samples each 
to represent the five HLA-G alleles currently known in 1999. They analyzed sequence from -
1437 to -793 and from -383 to 81. After sequencing, they reported seven SNPs (-1413, -1306, -
1179, -1140, -1121, -964, -201) and one deletion (-1233) in the promoter region (Hviid et al. 
1999). 
 
Variation in the HLA-G promoter region was next examined in relation to miscarriage. 
Forty-two Hutterite women and men were genotyped for the 14 base pair insertion/deletion in the 
3’ UTR and five of the seven promoter region SNPs reported by Hviid (Ober et al. 2003). The 
women experienced multiple conceptions including both miscarriages and successful 
 17 
pregnancies. These 42 individuals were specifically chosen to represent all eight HLA-G alleles, 
and not on the basis of reproductive history. Eighteen SNPs (-1306, -1179, -1155, -1140, -1138, -
1121, -964, -762, -725, -716, -689, -666, -633, -486, -477, -369, -201, -56) were found in the 
1300 bp region upstream of exon 1. One polymorphism, -725 was reported to be associated with 
fetal loss when both parents carried a G allele at this site. It was further shown that a G allele 
created a CpG dinucleotide (Ober et al. 2003).  
 
A study of 85 Danish individuals (43 women and 42 men) enrolled in IVF treatment 
supported Ober et al.’s suggestion of -725 being a factor in pregnancy outcomes. Of the 12 SNPs 
reported (-964, -762, -725, -716, -689, -666, -633, -486, -477, -369, -201, -56) SNP -725 was 
observed in samples with homozygous insertions for the 14 base pair marker in the 3’ UTR. 
These individuals did not have detectable soluble HLA-G (sHLA-G1) and HLA-G5 in serum 
screens, p =0.03 (Hviid et al. 2004c). Based on these findings, Hviid et al. concluded that 
variation in HLA-G gene’s promoter region leads to decreased levels of sHLA-G and may be of 
possible importance in preventing pregnancy complications (Hviid et al. 2004c). 
 
In order to determine the effect of nucleotide change at -725 and -1121 on haplotypes, a 
luciferase reporter assay was preformed on five selected HLA-G promoter haplotypes (Ober et 
al. 2006). The goal was to determine whether variation in the promoter region influenced 
transcription. Findings showed differences in expression levels between promoters, the 
haplotypes with a G allele at -725 had significantly higher expression levels compared to a C 
allele or T allele (Ober et al. 2006).  
 
In 2006 SNP -477 was highlighted to have a possible functional significance due to high 
levels of interleukin-10 (IL-10) (Hviid et al. 2006). Their population of 61 male and female 
Caucasian donors was genotyped for the 3’ UTR 14 base pair insertion/deletion and sequencing 
was analyzed between -762 an -400 from start site of transcription. Eleven SNPs (-762, -725, -
716, -689, -666, -646, -633, -509, -486, -477, -400), one insertion (-540) and one deletion (-533) 
were detected. Using PHASE 2.1 and the thirteen variants for analysis they reported eighteen 
haplotypes along with possible implications for IL-10 secretion from peripheral blood 
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mononuclear cells, instrumental in immune responses and immune escape or tolerance (Hviid et 
al. 2006). 
 
Most recent SNP counts were reported from DNA collected in African Americans, 
European Americans and Chinese individuals participating in an asthma study. Twenty-seven 
SNPs were found in the promoter region of HLA-G (Tan et al. 2005). These SNPs include the 
eighteen reported by Ober et al. in 2003 (see above) as well as variation at -990, -922, -810, -
646, -509, -483, -443, -400 and -391. With these 27 SNPs, thirteen different haplotypes were 
reported (Tan et al. 2005).  
 
The previous articles are the most informative when it comes to background studies of 
HLA-G. For additional articles of interest, see Appendix A. In summary, information concerning 
HLA-G and spontaneous abortion has been in the literature since 1996. Exon 2 and exon 3 are 
mostly used to identify the different HLA-G alleles when comparing samples in a study. The 14 
base pair insertion/deletion found in the 3’ UTR has received a substantial amount of attention in 
spontaneous abortions studies. And while the promoter region appears to be related to pregnancy 
loss, previous studies have had small populations and contradictory conclusions.  
3.3 MATERIALS AND METHODS 
Brief summaries of the materials and methods are discussed below; methods are described in 
more detail in the manuscripts that follow. 
3.3.1 Population 
Patient samples (cases) were collected from women who experienced two or more recurrent 
pregnancy losses. The cases were drawn from the general obstetrical population served by the 
University of Pittsburgh, Magee Women's Hospital and the University of Minnesota, Center for 
Reproductive Medicine. All protocols were approved by the Institutional Review Boards of the 
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University of Pittsburgh and the University of Minnesota and each participant gave written 
informed consent to participate. Details of the recruitment have been reported by Lanasa et al. 
2001. Briefly, idiopathic recurrent spontaneous abortion was defined by 1) having two or more 
clinically recognized spontaneous abortions and 2) having recurrent spontaneous abortion of 
unknown cause (Lanasa et al. 2001).  Women were excluded from enrollment if they were 
known to have abnormal hysterosalpinogram, antiphosophlipid antibodies, connective tissue 
disorder, if either parent had an abnormal karyotype (i.e. balanced translocation) and if the 
mother had skewed X-inactivation. Ages of participants ranged from 25-52 years, mean of 33.3 
years, median of 33 years and mode of 34 years. 
 
Control subjects were selected from healthy primiparous women aged 14-44 years who 
were seeking prenatal care prior to 20 weeks’ gestation at Magee-Womens Hospital in 
Pittsburgh, Pennsylvania. Of these women screened for possible participation in the study, 
factors such as planned delivery at another hospital or not being pregnant were deemed ineligible 
and removed from the study population. After enrollment, those women who experienced 
spontaneous abortion, termination of pregnancy, molar pregnancy or ectopic pregnancy were 
determined ineligible and removed from the study population. 
3.3.2 Genotyping 
High molecular weight DNA was isolated from EDTA anticoagulated whole blood using the 
PureGene kit (Gentra Systems). The MBL study consisted of 219 cases and 235 controls, while 
the HLA-G study included 238 cases and 233 controls. Differences in “n” (numbers) can be 
accounted for due to variation in genotyping and sequencing success across the studies. All 
populations consisted of Caucasian samples only.  
 
Mannose binding lectin genotyping included three mis-sense variants in exon 1 (R52C, 
G54D and G57E), each of which is associated with reduced levels of circulating MBL 
(Kilpatrick 2002), and two promoter variants which are known to influence the expression of the 
MBL gene (Juliger et al. 2000). The SNPs were analyzed individually by sequence specific 
priming-polymerase chain reaction (SSP-PCR), restriction enzyme digest or pyrosequencing. 
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 HLA-G promoter region alleles and haplotypes were defined by sequencing cases and 
controls. Two primer pairs were used due to the 1400 base pairs of HLA-G promoter region we 
were interested in. Selecting primers to sequence the promoter region of HLA-G was 
accomplished using the NCBI BLAST website http://www.ncbi.nlm.nih.gov/blast/Blast.cgi. It 
was important to verify that the primers chosen were unique to the promoter region of HLA-G. 
For this reason, after choosing the sets of primers, the sequences were reentered into BLAST and 
checked for homology with the HLA-G gene. SNPs at the HLA-G locus were identified by 
sequencing the coding and regulatory regions using the BigDye 3.1 terminator ready reaction kit, 
and running them on the Prism ABI 3730 fluorescent sequencer. We analyzed the aligned 
sequences using SEQUENCHER 4.5  (Gene Codes). The SNPs in exon 2 were identified using 
methods similar to the promoter region sequencing, while the 14 base pair insertion/deletion in 
the 3’ UTR was detected by PCR and gel electrophoresis on a 3% gel. All HLA-G sequence and 
variation was compared to the current sequence reported in SNPper (Appendix B). 
3.3.3 Data analysis 
Allele frequencies in both the MBL and HLA-G projects were estimated by gene counting and 
compared to the expectations of HWE by chi-square and Fisher’s exact test analysis. Gene 
counting was carried out using R Consol (R) (RDevelopmentCoreTeam 2005) to ensure 
accuracy. Odds ratio and power analysis were calculated using an interactive website (Statistics 
2004). We compared allele and haplotype frequencies in cases and controls to identify 
alleles/haplotypes that were non-randomly associated with recurrent pregnancy loss. R was used 
to calculate Fisher’s exact tests and to find odds ratios (RDevelopmentCoreTeam 2005). Chi-
square results were calculated using an interactive website (Preacher 2001). MATCH version 1.0 
was used to analyze TFBS (Quandt et al. 1995). All common and minor alleles were used in the 
TFBS searches in order to reveal binding sites that are both created and destroyed due to 
polymorphisms in the promoter region. Three consensus sequences were used to locate TFBS 
(Appendix C). Linkage disequilibrium was analyzed using Haploview (Barrett et al. 2005) and 
haplotypes were constructed using PHASE version 2.1.1 (Stephens 2006). 
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3.4 RESULTS 
3.4.1 Mannose binding lectin 
Case and control populations were genotyped for five sites that have been suggested to influence 
plasma MBL levels: -550, -221, codon 52, codon 54 and codon 57. All five sites were in Hardy-
Weinberg equilibrium (HWE). Cases and controls were grouped and predictions of high, 
intermediate and low plasma MBL levels were assigned; no significant differences were found 
between cases and controls, X2 =0.4098 p =0.8147. Cases were stratified by number of RSA to 
examine frequency of RSA with genotype. No relationship between plasma MBL levels and 
number of spontaneous abortions was found. Power analysis was performed and we detected 
80% power at p=0.05 to observe an odds ratio > 1.63 when comparing the high MBL plasma 
level group to medium and low plasma level groups combined. Therefore, this study was large 
enough to have shown an effect of RSA due to MBL haplotypes, if a relationship was present. 
3.4.2 Human leukocyte antigen-G 
The HLA-G study identified a total of 32 SNPs spanning the 1400 bp region downstream of exon 
1, 22 of which have minor allele frequencies greater than two percent. Two SNPs, -477 and -369, 
in the case population deviate significantly from Hardy-Weinberg expectations, p =0.0039 and p 
=0.0049 respectively. These same two SNPs were also found to be in strong LD with one 
another (LOD >2 D’ =1). Further analysis involved comparing counts at each SNP between case 
and control groups to determine if variation could be protective of, or account for, RSA. Three 
sites showed significant differences between case and control SNP frequencies, -486, -477 and -
369. Odds ratio calculations for these SNPs indicate an approximate 1.456 fold increase (CI 
=1.1077-1.9137) for risk of RSA.  
 
Results of the 3’ UTR insertion/deletion variation were in HWE and there was no 
significant difference between cases and controls, X2 =5.71, p =0.0576. Exon 2 was sequenced in 
order to provide HLA-G allele nomenclature. Of the six sites, four were in HWE and two sites 
had frequency of variations too low for accurate HWE testing.  
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 Forty-six TFBS were found in the HLA-G promoter regions. Of these 46, seven have a 5’ 
to 3’ core match that is altered by a presence or absence of an allele. Transcription factors 
affiliated include: Elk-1, Foxd3, Comp1, v-Myb, Hnf-4 and Cdp Cr1.  
 
Haplotype frequencies in case and control populations for exon 2 and the 3’ UTR 
polymorphism as well as for the promoter region were calculated (Appendix G and Appendix F). 
Many HLA-G papers in the literature define individuals by HLA-G nomenclature based on 
specific variation in exon 2, exon 3 and the 3’ UTR. In our samples, exon 2 and the 3’ UTR 14 
bp polymorphism were analyzed in order to identify HLA-G allele nomenclature and compare it 
to the alleles found by other investigators. Six sites, originally identified by others, in exon 2 
were genotyped: 188, 294, 374, 410, 484 and 487. We were able to distinguish 16 haplotypes in 
our case and control population (Appendix D). Allele frequency differences between case and 
control populations for the 16 haplotypes were not significant, p =0.48. While we found six sites 
of variation in Exon 2, three sites are usually discussed and include 294, 374 and 410. Therefore 
we also performed analysis after removing SNPs 188, 484 and 487 in order to provide 
nomenclature comparable to that which is in the literature (Appendix E). Promoter region 
haplotypes were constructed; a total of 55 different haplotypes were found in the case and 
control population (Appendix F).  Haplotype frequencies in cases and control groups did not 
differ significantly, p =0.06, although a trend towards significance is observed.  
  
To define LD across the promoter region we used Haploview. SNP data was analyzed for 
cases and controls together, (Appendix I) as well for the two individual groups (Appendix J and 
Appendix K). LD between SNPs and across LD blocks was summarized. We are able to 
conclude that there is LD across the 1400 bp of promoter region upstream of exon 1. 
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4.0  MANNOSE BINDING LECTIN MANUSCRIPT 
The following manuscript was submitted to the American Journal of Obstetrics and Gynecology 
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This study found no evidence to support a relationship between mannose binding lectin 
genotypes, or phenotypes, and the risk of recurrent spontaneous abortion.
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Mannose binding lectin genotypes are not associated with recurrent spontaneous abortion  
Dara S Berger, W Allen Hogge, Susan DeCroo, Robert E Ferrell 
 
Objective: Infectious agents are known to cause pregnancy loss; an infectious etiology for 
recurrent spontaneous abortion (RSA) has been proposed. Low mannose binding lectin (MBL) 
plasma levels, a factor in innate immunity, is an explanation for severe infantile infection and has 
been proposed as a cause of RSA.  
Study Design: To test the hypothesis that MBL genotypes, leading to reduced levels of 
circulating MBL, are significantly more frequent among women experiencing idiopathic RSA, 
we conducted a case (n=219)/control (n=235) study of RSA.  Subjects were genotyped for 
promoter variations and missense mutations in exon 1.  
Results: Populations genotyped are in Hardy-Weinberg equilibrium. Fisher’s exact test is not 
significant, p-values all >0.05. Number of miscarriages and a presence of live births are 
unaffected by predicted MBL plasma level.  
Conclusion: No association is observed between MBL genotypes or predicted MBL plasma 
levels and risk of recurrent pregnancy loss among women with unexplained RSA. 
 
Key Words: Mannose binding lectin, Recurrent spontaneous abortion, Genotyping 
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INTRODUCTION 
 
Recurrent spontaneous abortion (RSA) is the most common pregnancy complication with the 
majority of cases having unknown causes. RSA was defined by Lanasa et al. 2001 as two or 
more clinically recognized spontaneous abortions. Because the prevalence of RSA is higher than 
expected by chance, it has been suggested that some couples have an underlying systemic cause 
for repeated pregnancy loss 1. A number of factors have been identified for RSA and include: 1) 
anatomic abnormalities of the uterus or cervix, 2) cytogenetic disorders such as recurrent 
aneuploidy or parental balanced translocations, 3) endocrine factors such as inadequate luteal 
phase, thyroid dysfunction, or diabetes, 4) reproductive tract infections, 5) immunologic causes 
such as anticardiolipin syndrome 2, 3 and 6) female carriers of X linked recessive male-lethal 
traits4. These etiologies, however, explain causes of recurrent pregnancy loss in only 20 to 50% 
of cases, depending on the indication for referral 5-8.  
 
Several bacterial and viral infectious agents have been proposed as a cause for 
miscarriage 9. It is known that the presence of pathogenic organisms in the maternal genital tract 
or placenta result in poor pregnancy outcomes 1, 10, 11. This suggests pregnancy outcome may be 
determined by maternal or fetal-host immune response. Mannose binding lectin (MBL), one of 
many elements of the innate immune system, has been indicated as an important component in 
successful pregnancy. Low MBL concentration has been proposed to be a risk factor for 
spontaneous abortion (SA) 12. It has been confirmed that plasma MBL concentrations are 
determined by a combination of genotypes and polymorphisms in both MBL coding and 
promoter sequence 13, 14. Three different variant alleles coding for structurally abnormal proteins 
have been identified in codons 52, 54 and 57 of exon 1 in the MBL2 gene located on 
chromosome 10q11.2-q21 15. Two single nucleotide polymorphisms (SNPs) lie in the proximal 
promoter at positions -550 and -221 of the flanking 5‘ region of the MBL2 gene 16, which also 
influences protein coding. Ninety percent of individuals who are homozygous for the wild type 
structural gene have MBL concentrations >0.6 ug/ml, while the majority of heterozygotes have 
plasma MBL levels <0.06 ug/ml 14, 17. Individuals who were homozygous or compound 
heterozygous for the less common alleles had MBL plasma concentrations of <1% of the wild 
type concentrations.  
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 Plasma levels of MBL are largely genetically determined and can be predicted by 
examining SNPs in the MBL gene and surrounding sequence 15. We therefore tested the 
hypothesis that MBL genotypes leading to reduced levels of circulating MBL are significantly 
more frequent among women who have experienced idiopathic recurrent pregnancy loss.  
 
MATERIALS AND METHODS 
 
The cases (n=219) are Caucasian women who experienced two or more recurrent pregnancy 
losses. They were drawn from the general obstetrical population served by the University of 
Pittsburgh, Magee-Womens Hospital and the University of Minnesota, Center for Reproductive 
Medicine. The Institutional Review Boards of the University of Pittsburgh and the University of 
Minnesota approved all protocols, and each participant gave written informed consent. Details of 
the recruitment have been reported by Lanasa et al. 4. Briefly, idiopathic RSA was defined by: 1) 
having two or more clinically recognized spontaneous abortions and 2) having RSA of unknown 
cause.  Women were excluded if they were known to have abnormal hysterosalpinogram, 
antiphosophlipid antibodies, connective tissue disorder, skewed X-inactivation, or if either parent 
had an abnormal karyotype (i.e. balanced translocation). Control subjects (n=236) were selected 
from healthy Caucasian women aged 14-44 years, who were seeking prenatal care at Magee-
Womens Hospital in Pittsburgh, Pennsylvania and known to have a normal pregnancy outcome.  
 
High molecular weight DNA was isolated from EDTA anticoagulated whole blood using 
the PureGene kit (Gentra Systems). Mannose binding lectin genotyping included three missense 
variants in exon 1 (R52C, G54D and G57E) and two functional promoter variants (-550 C>G 
and -221 G>C). To detect polymorphisms at -550, DNA was subjected to sequence specific 
priming-polymerase chain reaction (SSP-PCR) 14.  Briefly, this method uses twin-pair primers to 
detect allelic nucleotides differentially18. Methods are described in detail by Matsushita et al. 
1998. The -221 site was investigated by the methods from Roelofs et al. 2003. PCR was carried 
out, the amplification product was digested by BasJI, and the fragments were separated by 
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electrophoresis through agarose gels 19. Exon 1 SNPs were identified by pyrosequencing using 
amplification 20. Primers were: forward 5’-CGTCTTACTCAGAAACTGTGACCTGTGAGG-3’ 
and reverse 5’-TTCCTCTGGAAGGTAAAGAATTGCAG-3’ with an internal sequencing 
primer: 5’-GGTTCCCCCTTTTCT-3’. 
 
Genotype frequencies were estimated by gene counting and compared to the expectations 
of Hardy-Weinberg equilibrium by chi square analysis and Fisher’s exact test. Dipolotypes were 
estimated and classified based on methodology as described in Baxter et al. 1. Allele and 
genotype frequencies were compared in cases and controls using chi square contingency table 
analysis. 
 
RESULTS 
 
A total of 219 cases and 236 controls were genotyped for the 5 polymorphisms, Table 1. Overall 
the number of miscarriages in the case population ranges from 2 SA to 10 SA per patient (mean 
= 3.575, median = 3, Figure 1). In patients with more than 4 SA the mean number of losses per 
patient is 6.636.  
 
The case and control populations genotyped are in Hardy-Weinberg equilibrium, at all 
five sites. Fisher’s exact test of cases and controls is not significant at each of the 5 sites, p-
values for -550, -221, codon 52, codon 54 and codon 57 are 0.7803, 0.3867, 0.2933, 0.8051 and 
0.6046 respectively (Table I). 
 
Plasma MBL concentration is determined by a combination of genotypes and is 
influenced by mutations in the structural gene as well as by two dimorphic loci in the promoter 
region 13, 14. Therefore we classified our cases and controls as high, intermediate and low in 
predicted MBL plasma concentrations. 
 
Using the classification methods described by Baxter et al. 1, it is possible to define the 
collection of genotypes as phenotypes (Figure 2). There is no significant association in cases and 
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controls between number of spontaneous abortions and predicted plasma levels of MBL (2 
degrees of freedom, X2= 0.4098, p= 0.81472) nor is there an association between lack of live 
births and MBL levels (2 degrees of freedom, X2=0.6620, p=0.7182). There is no association 
between a history of RSA and multi-SNP genotypes at the MBL locus. There is no significant 
difference in risk of RSA and plasma MBL levels (high, intermediate, low) with number of SA 
in cases and controls.  
 
COMMENT 
 
In a recent study of 217 women with three or more unexplained SA, Kruse et al. 21 reported 
women with low maternal serum MBL levels had a higher abortion rate than patients with 
normal MBL levels 21. A similar study of 146 Danish women and 49 Scottish women with three 
or more unexplained SA reported MBL deficiency was found with increased frequency among 
women with RSA in both populations, reaching statistical significance in the Scottish population 
22. These and other studies suggest that MBL levels could account for previously unexplained 
RSA. However, Baxter et al. in 2001 published contradictory results of recurrent miscarriage and 
MBL, stating no association between recurrent miscarriage and variant alleles in the MBL gene. 
Our study too has shown recurrent spontaneous abortion is not influenced by MBL genotypes, 
supporting Baxter et al. 1. 
  
Traditionally RSA has been defined as three or more spontaneous, consecutive pregnancy 
losses. It has been reported that patients with a single live born followed by a series of 
miscarriages have similar disorders to those patients with only miscarriages 23. Also, because risk 
of recurrent miscarriage increases with each prior miscarriage it has been argued that evaluation 
can begin after two losses instead of waiting until three 24. The RSA criteria of two or more 
miscarriages were required for eligibility in this study, as opposed to the RSA definition of three 
or more recurrent pregnancy losses. It is our belief that the population used gives a broader range 
of pregnancy loss cases and results in a more comprehensive genotyping study. Due to 
differences in the definition of RSA, it was therefore important to determine if women with 2 SA 
would have similar phenotypes to those women experiencing 3 or more SA. It is clear from 
Figure 2 that had we examined women experiencing 3 or more SA, leaving out the population 
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experiencing 2 SA, the results would not have changed. Our case population does not produce 
significantly different levels of MBL than our control population. 
 
Investigating MBL plasma levels in pregnant mothers implies we are studying a maternal 
condition or phenotype; the influence of a genotype. The mechanism we propose involves 
women with low MBL plasma levels being at an increased risk for recurrent miscarriage because 
of their diminished ability to detect and fight infection. This would result in potentially every 
pregnancy being lost to miscarriage if exposed to maternal genital tract infection. Eighty of our 
cases experienced two or more miscarriages with no live births and were observed to have 
similar predicted MBL plasma levels to our control population, p=0.7182, Figure 2. Having no 
live births does not impact predicted MBL plasma levels in women suffering from RSA. One 
suggestion to further strengthen these findings would be future analysis of infection rates and 
rates of exposure to infections in the populations studied. 
 
The diplotypes analyzed in this study were estimated based on previous findings 1. Given 
that we did not measure plasma levels in each case and control, our findings rely on the reported 
diplotype frequencies and relationships previously reported. Given the consensus in the 
literature, we are confident that our methods of estimating MBL concentrations were true and 
informative.  
 
Given our sample size of 219 cases and 235 controls, we had 80% power (at p=0.05) to 
detect an odds ratio ≥1.63 when comparing the proportion of individuals with genetically 
determined high MBL levels versus individuals with genetically determined intermediate or low 
MBL levels between the two groups.  If the true odds ratio, between individuals with high MBL 
levels compared to individuals with intermediate and low MBL, is less than 1.63 we would not 
have adequate power to detect significant differences. 
 
Despite prior smaller studies 13, 21, 22 of a correlation between reduced plasma MBL levels 
and RSA, we find no evidence to support a relationship between MBL genotypes or phenotypes 
and risk of RSA among Caucasian women. Our conclusion is to reject the hypothesis that 
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genetically determined levels of plasma MBL are related to the risk or number of idiopathic 
spontaneous abortions in Caucasian women. 
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Figure 1: Categorization of spontaneous abortion cases (n=219) according to number of 
miscarriages experienced. 2 SA, 3 SA, 4 SA and 4 or more SA are depicted, n=51, 87, 44 and 37 
respectively. 
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Figure 2: Percent of classified MBL production in comparison with the number of 
spontaneous abortions. Each individual, in cases and controls, was classified by predicted MBL 
plasma level concentration and separated by number of miscarriages. 
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Table 1: Genotype counts and minor allele frequency (q) of MBL alleles affecting mannose binding lectin 
concentrations. 
     
  -550 -221 Codon 52 Codon 54 Codon 57 
Cases            
  CC: 92 GG: 127 CC: 199 GG: 159 GG: 213
  CG: 96 GC: 84 CT: 20 GA: 56 GA: 6
  GG: 31 CC: 8  AA: 4   
q 0.3607 0.2283 0.0457 0.1461 0.0137 
Controls         
  CC: 97 GG: 150 CC: 207 GG: 178 GG: 226
  CG: 110 GC: 76 CT: 29 GA: 54 GA: 9
  GG: 29 CC: 10   AA: 4   
q 0.3559 0.3649 0.0614 0.1314 0.0191 
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A comprehensive analysis of HLA-G’s promoter region and the implications for recurrent 
spontaneous abortion 
 
ABSTRACT 
 
Background: Miscarriage is one of the most common pregnancy complications. Recurrent 
spontaneous abortion (RSA) is defined as two or more pregnancy losses. Human leukocyte 
antigen-G (HLA-G) is a ligand for natural killer (NK) cell receptors and has the ability to block 
NK cell activity, which if not blocked can potentially harm a fetus. Consequently a deletion or 
mutation of the HLA-G gene could lead to miscarriage. 
 
Study design: Cases (n=238) include Caucasian women experiencing two or more spontaneous 
abortions (SA) and controls (n=233) include women with at least one live birth and no history of 
SA. Sequencing was performed for 1400 base pairs (bp) of HLA-G’s promoter region, 
genotyping for the 14 bp insertion/deletion was carried out and haplotypes and diplotypes were 
constructed using information from sequencing.  
 
Results: Twenty-three single nucleotide polymorphism (SNPs) were observed in the promoter 
region with a minor allele frequency >0.02. Twelve SNPs differed significantly in frequency 
between cases and controls. Two haplotypes incorporating these 12 SNPs differed significantly 
in frequency between cases and control populations. Cases also had a higher frequency of 
individuals homozygous for the 14 bp insertion. Linkage disequilibrium (LD) was detected 
throughout the 1400 bp promoter region.  
 
Conclusion: Cases and controls differed significantly in frequency of both individual SNPs and 
resulting haplotypes. We therefore conclude that RSA is associated with promoter region 
polymorphisms in the HLA-G gene.  
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INTRODUCTION   
 
Approximately one in four pregnant women experiences at least one pregnancy loss, making 
spontaneous abortion the most common pregnancy complication (Wilcox et al. 1988). This 
prevalence is higher than expected by chance and suggests that some couples have an underlying 
systemic cause for repeated pregnancy loss (Baxter et al. 2001). Recurrent spontaneous abortion 
(RSA) can be defined as two or more clinically recognized spontaneous abortions (Lanasa et al. 
2001).  
 
RSA may be a result of maternal immune system recognition of paternal antigens on the 
feto-placental unit, followed by damage to fetal cells and abortion (Laird et al. 2003). The 
mechanisms that protect a pregnancy from the maternal immune system are not well understood. 
Therefore immunological assessment of normal pregnancy, let alone abnormal pregnancy, is 
challenging (Laird et al. 2003). Human leukocyte antigen-G (HLA-G) is an HLA-class I gene 
located in the major histocompatibility complex (MHC) on chromosome 6, and is expressed at 
the maternal-fetal interface. Uterine natural killer (uNK) cells are present in and around 
trophoblast cells and can cause fetal damage if not properly regulated. HLA-G is expressed on 
fetal extravillous trophoblasts (EVT), placental macrophages and mesenchymal chorionic villi. 
Trophoblast cells are known to be immunologically inert, lacking MHC I or MHC II molecules. 
Without MHC molecules the cells would be destroyed. However HLA-G is believed to inhibit 
trophoblast damage caused by natural killer (NK) cells during pregnancy, potentially protecting 
the fetus’s genetically dissimilar cells from the mother’s immune system. Because of HLA-G’s 
proximity to fetal and maternal tissue, which are genetically different from each other, and its 
role in immune defense, it is likely that HLA-G expression and subsequent interaction with uNK 
cells and killing inhibitory receptors, is a potential factor in all pregnancies, whether successful 
or unsuccessful. Consequently, a deletion or mutation in the HLA-G gene could lead to loss of 
the fetus in early pregnancy (Rouas-Freiss et al. 1997). 
 
Although the biology of HLA-G suggests a possible involvement in successful 
pregnancy, the exact function of HLA-G is unknown; thus, its role in pregnancy is beneficial to 
investigate. The majority of HLA-G studies have focused on three single nucleotide 
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polymorphisms (SNPs) in exon 2, three SNPs in exon 3 as well as a 14 base pair (bp) 
insertion/deletion in the 3’ untranslated region (UTR). Exon polymorphisms revealed HLA-G 
allele *01014, *010102, *0105N, *010108 and possibly *01013 (studies are contradictory) to be 
associated with RSA (Abbas et al. 2004; Aldrich et al. 2001; Hviid and Christiansen 2005; 
Pfeiffer et al. 2001). The 3’ UTR has conflicting findings concerning the 14 bp insertion/deletion 
in RSA as well. One report suggests homozygosity for the insertion is associated with increased 
risk of RSA and heterozygotes are less frequent in RSA groups (Hviid et al. 2004a). In contrast, 
others find that heterozygotes are more frequent in RSA populations (Tripathi et al. 2004) 
compared to another study reporting heterozygotes are less frequent in RSA case (Hviid et al. 
2002).  
 
Eighteen SNPs were initially identified in the HLA-G promoter region in Hutterite 
couples who experienced both fetal loss as well as successful pregnancy (Ober et al. 2003). More 
recently this group has updated their findings to include 27 SNPs (Tan et al. 2005). Single 
nucleotide polymorphisms defining eight HLA-G promoter haplotypes have been identified and 
differentially associated with risk of miscarriage in the Hutterites (Ober et al. 2003).  
 
Although the most frequently studied, SNPs are not the only factors in a gene to influence 
function and protein synthesis. The promoter region is the sequence before exon 1 that initiates 
and regulates the transcription of a gene. Protein binding sites in a promoter are known as 
transcription factor binding sites (TFBS). These are short sequences, made up of core and matrix 
sequence, totaling approximately 10-20 base pairs, which enable specific recognition by a 
corresponding transcription factor (TF). Transcription initiation influences whether a gene is 
expressed and consequently how much protein is produced (Cartharius et al. 2005). The ability to 
predict potentially functional TFBS is important to promoter analysis (Cartharius et al. 2005).  
 
If functional HLA-G is important in successful pregnancy, then molecular methods such 
as screening for variation in HLA-G may be beneficial in identifying individuals at risk of 
recurrent pregnancy loss. In order to assess association between RSA and genotype we studied 
case and control populations for HLA-G polymorphisms in the promoter region. We predicted 
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there would be a relationship between the presence of certain HLA-G alleles and an increased 
risk for recurrent pregnancy loss.  
 
METHODS 
 
The cases (n=238) were Caucasian women who experienced two or more recurrent pregnancy 
losses. The Institutional Review Boards of the University of Pittsburgh and the University of 
Minnesota approved all protocols, and each participant gave written informed consent. Details of 
the recruitment have been reported by Lanasa et al. 2001. Briefly, idiopathic RSA was defined 
by: 1) having two or more clinically recognized spontaneous abortions and 2) having RSA of 
unknown cause.  Women were excluded if they were known to have abnormal 
hysterosalpinogram, antiphospholipid antibodies, connective tissue disorder, if either parent had 
an abnormal karyotype (i.e. balanced translocation) and if the mother had skewed X-inactivation. 
Mean, median and mode for the patient population were 33.46 years, 33 years and 34 years 
respectively. Control subjects (n=233) were selected from healthy Caucasian women aged 14-44 
years, who were seeking prenatal care prior to 20 weeks gestation at Magee-Womens Hospital in 
Pittsburgh, Pennsylvania.  
 
High molecular weight DNA was isolated from EDTA anticoagulated whole blood using 
the PureGene kit (Gentra Systems, Minneapolis, MN). We were interested in the 1400 bp region 
of the promoter adjacent to the coding region of the HLA-G gene. Primer pairs (PF2 and PR2; 
PF4 and PR4) were designed with overlapping amplification products of ~75 bp so that the entire 
region of interest was amplified (Table I). DNA was amplified by polymerase chain reaction 
(PCR) on a Bio-Rad MJ Thermal Cycler (Richmond, CA) with an initial denaturing step of 95 
degrees Celsius (C) for 2 minutes, followed by 35 cycles each of 94 degrees C for 30 seconds, 58 
degrees C annealing for 30 seconds and 72 degrees C for 30 seconds, with a final extension step 
of 72 degrees C for 1 minute. An EXO Sap step was performed on the PCR products generated 
from the primer sets in order to remove excess primers and deoxyribonucleotide triphosphates 
(dNTPs). EXO Sap products were cycle sequenced using the Big Dye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, Foster City, CA) according to manufacturer’s instructions, 
and then electrophoresed through an ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, 
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CA) at the University of Pittsburgh’s Genomics and Proteomics Core Sequencing Facility. 
Sequence analysis was completed using Sequencher v4.5 RC2 (Gene Codes Corporation). In 
order to compare results with previous studies we sequenced exon 2 as well. Exon 2 analysis was 
similar to promoter region analysis; primers used were Exon2F with Exon2R (Table I). 
 
The 14 bp insertion/deletion in the 3’ UTR was investigated via PCR and gel 
electrophoresis, using primers IDF and IDR (Table I). Samples were amplified on a Bio-Rad MJ 
Thermal Cycler (Richmond, CA) at 95 degrees C for 5 minutes, followed by 45 cycles of 95 
degrees C for 30 seconds, 52 degrees C for 30 seconds and 72 degrees C for 30 seconds, with a 
final extension of 72 degrees C for 5 minutes. Samples were electrophoresed through a 3% 
agarose gel. Insertions and deletions were interpreted by two independent investigators. 
 
R Consol was used to count SNPs and to calculate Fisher’s exact tests and odds ratios 
(RDevelopmentCoreTeam 2005). Chi-squared results were calculated using an interactive 
website (Preacher 2001). MATCH version 1.0 was used to analyze TFBS (Quandt et al. 1995). 
All common and minor alleles were used in the TFBS searches in order to reveal binding sites 
that are both created and destroyed due to polymorphisms in the promoter region. Linkage 
disequilibrium was analyzed using Haploview (Barrett et al. 2005).  
 
Haplotypes and diplotypes were constructed using Phase v2.1.1 (Stephens 2006). A 
diplotype consists of haplotype pairs from one individual, in this study the mother. One 
haplotype is passed to an offspring for each parent and Phase software is able to analyze both 
haplotypes and diplotypes allowing for analysis of possible maternal diplotypes and possible 
maternal haplotypes, one of which is inherited by the fetus. 
 
RESULTS 
 
Promoter region sequence 
Sequencing of the cases’ and controls’ DNA inclusively between -1305 and -201 bp identified 23 
SNPs with minor allele frequencies greater than two percent (Table II). All SNPs were in Hardy-
Weinberg equilibrium (HWE) in the control samples. Two SNPs in the cases deviated 
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significantly from Hardy-Weinberg expectations, -477 and -369 p-values 0.0039 and 0.0049 
respectively. SNP -725, which has three alleles, is not included in Table II. Frequencies for C, G 
and T alleles at this locus in controls were 0.8201, 0.1495, and 0.0304 respectively whereas those 
for cases were 0.8146, 0.1313, and 0.0542 respectively. 
 
Twelve SNPs differed significantly in allele frequency between cases and controls (Table 
III). Odds ratios for these 12 SNPs  (Table III) indicated there is approximately a 1.456 fold 
increase in the presence of one allele over another, confidence interval (C.I.) 1.0705-1.8285.  
 
Fourteen base pair insertion/deletion 
The 3’ UTR of HLA-G has a 14 base pair insertion/deletion. Cases and controls were in HWE 
and were not significantly different from each other, X2= 5.71 p=0.058 (Table II). Five of the 
samples in the case population were not typed for the insertion/deletions analysis because of poor 
amplification. 
 
Transcription factor binding sites 
We identified 46 potential TFBS matches within the HLA-G promoter region. Of these, seven 
have a 5’ to 3’ core match that is changed by the presence or absence of an allele. These seven 
affected SNPs include -1179, -1155, -762, -689, -486 and two at -201. The factors involved are 
Elk-1, Foxd 3, Comp 1, v-Myb, Hnf-4 and Cdp Cr1. The percentage core match for each TFBS 
is ≥76.5%. 
 
Haplotype and diplotype data 
We first constructed haplotypes using all 23 variants present in case and controls. We identified a 
total of 55 haplotypes in our population. Phase calculations indicate that neither promoter region 
nor exon 2 haplotypes differed significantly in frequency between cases and controls, p=0.06 and 
p=0.48 respectively. We kept exon 2 haplotypes separate from promoter region haplotypes 
because an excess of haplotypes were created when all the SNP data were combined; separate 
analysis was more useful in case and control comparison. Eight promoter-region haplotypes for 
cases and controls had frequencies >1% (supplemental Table VIII) and accounted for 
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approximately 90% of the haplotypes in our samples. Diplotype testing showed no significant 
haplotype pairs at p<0.01. 
 
We repeated the haplotype analysis using the twelve SNPs which differed significantly in 
frequency between cases and controls (Table III). This time, 28 haplotypes were identified. Two 
haplotypes (AGATGGTACGAA [haplotype 13] and GAGCTAGGACCG [haplotype 19]) were 
significantly more frequent in one population than the other (Table IV). Again diplotype analysis 
did not reveal significant findings. 
 
Linkage disequilibrium (LD) for the entire population, as well as for cases and controls 
separately, was analyzed using Haploview (Figure 1). The average D’ value of SNPs across the 
1400 bp regions was >0.95, indicating strong LD. Interestingly, the Haploview images of LD for 
case populations and control populations appear to be different (Figure 1B and 1C). For example 
in the controls, site -1138 has LOD<2, D’<1 and -486, -391 and -369 have LOD<2 D’=1 which 
indicates weaker LD. In contrast, the cases exhibit strong LD at these same locations, LOD≥2, 
D’=1. These results suggest a higher frequency of common haplotypes in the cases than in the 
controls. However, the controls also have an increase in rare variants that are not present in the 
case population, which may cause a gap at certain locations in the LD image. 
 
DISCUSSION 
 
Traditionally RSA has been defined as three or more spontaneous, consecutive pregnancy losses. 
It has been reported that patients with a single live birth followed by a series of miscarriages 
have similar disorders to those patients with only miscarriages (Clark et al. 2001). Also because 
risk of recurrent miscarriage increases with each prior miscarriage it has been argued that 
evaluation should begin after two losses instead of waiting until three (ACOG 2001). The RSA 
criteria of two or more miscarriages were required for eligibility in this study, as opposed to the 
RSA definition of three or more recurrent pregnancy losses. It is our belief that the population 
used gives a broader range of pregnancy loss cases and results in a more comprehensive 
genotyping study. RSA, consecutive or not, allows for the possibility of a genetic mutation 
which if recessive, would occur in 25% of conceptions; live births could be interspersed with 
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miscarriage(s). The case population includes these individuals, as well as those experiencing two 
or more SA, whereas a study requiring three or more consecutive miscarriages would have 
eliminated their participation. This becomes important because HLA-G is expressed on 
trophoblast cells and is of fetal origin, therefore we are considering a fetus’s maternally inherited 
risk and each pregnancy will be dependant on the fetus’s HLA-G expression. An individual who 
experiences two or more non-consecutive spontaneous abortions is more likely to have 
miscarried due to genetic factors, and should be included in this analysis, as opposed to 
experiencing loss due to maternal causes such as medical illness, hormonal issues or anatomic 
causes (Clark et al. 2001).  
 
Insertion/deletion data for the 3’ UTR were similar for cases and controls in our study. 
The frequency of the 14 bp deletion was 56.438% in cases and 62.876% in controls. The number 
of heterozygotes was lower in cases, n=97, than in controls, n=107, which contrasts reports by a 
previous study that showed significantly more heterozygotes in the case population, X2=6.014, 
p<0.01 (Tripathi et al. 2004). Our results could vary due to ethnic differences; our study was 
conducted in the United States and the other was conducted in India. Furthermore we were able 
to exclude cases with abnormal chromosomes, anatomic irregularity and endocrine disorders. 
Our data are more consistent with research by Hviid et al. 2002 who reported a significantly 
greater number, according to HWE, of heterozygotes for the 14 bp polymorphism in controls. 
Homozygotes for the insertion were more frequent in cases than controls (Hviid et al. 2002), 
which corresponds with our findings.  
 
Factor Hnf-4 has a TFBS interrupted by SNP -486, which is of interest because this SNP 
differs significantly in allele frequency between cases and controls. However, Hnf-4 is currently 
not known to play a role in decidua formation, pregnancy or miscarriage. Of the five other TFs 
associated with potential HLA-G promoter binding site identified in this study, Elk-1, Foxd3, 
Comp1, v-Myb and Cdp Cr1, only one (Foxd3) has a connection to pregnancy. It has been 
demonstrated that Foxd3 is required in the trophoblast progenitor cell line in murine embryos 
(Tompers et al. 2005). The binding site for Foxd3 is created by a G allele at SNP -1155. 
However, both the cases and controls had high frequencies of G alleles at -1155, and the allele 
frequencies were not significantly different between the two groups. Nevertheless, we did 
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identify two cases who were homozygous for the minor alleles and one control individual 
homozygous for the minor allele at this site. It is possible that the groups did not have 
significantly different allele frequencies at -1155 because selection has already taken place to 
eliminate variation in cases and controls. 
 
Consistent with previous reports, we have determined that there is variation in the 
promoter region of HLA-G. Other investigations have reported that the odds ratio for pregnancy 
loss among couples with the G allele at -725 is 2.76, confidence interval (CI) 1.08 - 7.09 (Ober et 
al. 2003; Ober et al. 2006) . These authors proposed that promoters with a G allele at -725 allele 
and perhaps a T allele at -1121 would have increased HLA-G expression which would negatively 
affect pregnancy outcome (Ober et al. 2006). However, our analysis did not reveal SNP -725 or -
1121 to be significant when comparing frequencies of the C, G or T alleles in cases and controls. 
Previously, a SNP at -477 was associated with IL-10 concentrations, but only before statistical 
correction (Hviid et al. 2006). The authors initially believed -477 to be influential due to its 
proximity to a heat shock element (Hviid et al. 2006). Because heat shock elements are important 
for transcription, a variant in the sequence could be significant. Our investigations support this 
study as we found SNP -477 allele frequencies to be one of 12 SNPs that differed significantly in 
allele frequency between cases and controls.   
 
Sequencing revealed haplotype variation could be a risk factor for RSA and it is likely 
that a combination of SNPs play a role in RSA. Twelve SNPs were identified to differ 
significantly in allele frequency between cases and controls, p-values < 0.05 (Table III). These 
12 SNPs have similar odds ratios suggesting one SNP is no more important than another. 
Haplotype 19 is significantly more common in RSA controls than cases, p=0.0004, whereas 
haplotype 13 is significantly more common in cases, p=0.00782 (Table IV). Given this 
information we conclude haplotype 13 to be a risk factor for RSA whereas haplotype 19 is likely 
to be protective against RSA. Furthermore, by examining the LD in the cases, Figure 1B, we 
show the presence of shared haplotypes, which further strengthens the theory of variants being 
linked. Given this information we then went on to test diplotypes. Both diplotype and haplotype 
information are important because of the fetal genotype’s implications. We did not see 
significant findings in diplotype analysis. One explanation is that HLA-G is expressed on 
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trophoblast cells which are of fetal origin yet we were constructing maternal diplotypes. Had we 
analyzed fetal DNA, we would have been more likely to see diplotype associations. 
 
Novel findings include three SNPs in the promoter region, -486, -477 and -369 whose 
allele frequencies differed significantly between cases and controls, p-values <0.005 (Table III). 
Sites -477 and -369 were in strong LD, LOD=197.39 D’=1.0. Our findings suggest that having 
an A allele at -486 could be protective against RSA. Also the likelihood of a G allele at -477, 
which corresponds to having an A allele at -369, could indicate susceptibility to RSA. Although 
these three SNPs do suggest a relationship to RSA, we strongly believe there are haplotype 
factors, not individual SNP variations, associated with RSA because of the strong LD across the 
1400 bp promoter region sequenced. 
 
HLA-G is expressed in all EVT populations including the cytotrophoblast cells, 
interstitial trophoblasts, endovascular trophobalsts and placental cells (Agrawal and Pandey 
2003). When considering HLA-G’s influence on pregnancy, it is important to take into account 
that HLA-G is found on trophoblasts at the maternal-fetal interface, and that they are considered 
to be the primary expresser of HLA-G. These trophoblast cells however are of fetal origin, not 
maternal origin; meaning that HLA-G nucleotide structure is based on genetic information from 
both the mother and father. For this reason it is questionable as to whether examining maternal 
HLA-G variation and diplotypes is the most effective method of studying HLA-G in women 
experiencing RSA. HLA-G has frequently been reported to play a role in immunity as well as in 
pregnancy loss, however too often the focus has been on maternal HLA-G status as opposed to 
fetal. We have attempted to compensate for this potential weakness by looking at haplotypes. 
One maternal haplotype is inherited by the fetus and therefore affects trophoblast HLA-G 
expression or lack of expression. To test our hypothesis further, sequencing of fetal DNA would 
be useful. However obtaining a sample of fetal DNA would be challenging. In the future we 
could sequence the paternal HLA-G promoter region in order to predict the fetal diplotype and 
attempt to compare miscarriages to fetal genotype.  
 
Based on our study, we believe that polymorphism in the promoter of HLA-G influences 
RSA, but because of strong LD across the region, haplotype differences, rather than individual 
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nucleotide variation are more important. By grouping SNPs into haplotypes we were able to 
condense and utilize all promoter region allele information simultaneously. Furthermore, TFBSs 
located in the promoter region may be created or destroyed depending on an individual’s 
haplotype, therefore affecting the likelihood of successful pregnancy.  
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Table I: Primer names, direction and sequences used for RSA case and control analysis. 
 
Primer name Sequence (5’-3’) 
PF2 5’-CTGAACACTTACAACTGTGAGG-3’ 
PR2 5’-CCGACACAGGTTAGGAGAAGG-3’ 
PF4 5’-GATACGCACACTAGTTAC-3’ 
PR4 5’-CCAGGACATCTCCTCAAG-3’ 
Exon2F 5’-GAGGGTCGGGCGGGTCTCAAC-3’ 
Exon2R   5’-GCATGGAGGTGGGGGTCGTGA-3’ 
IDF 5’-GTGATGGGCTGTTTAAAGTGTCACC-3’ 
IDR 5’-GGAAGGAATGCAGTTCAGCATGA-3’ 
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Table II: Allele frequencies for SNPs with minor frequencies (q) greater than two percent.  
 
    Cases        Controls     
    HWE    HWE 
Location 
 
Alleles p q p 
value 
 
Alleles p q p 
value 
Promoter           
-1305  A=G 0.5 0.5 0.2  G→A 0.588 0.412 0.92
-1179  G→A 0.556 0.444 0.07  A→G 0.54 0.46 0.9
-1155  G→A 0.884 0.116 0.78  G→A 0.914 0.086 0.88
-1140  A→T 0.622 0.378 0.42  A→T 0.667 0.333 0.92
-1138  A→G 0.949 0.051 0.15  A→G 0.972 0.028 0.91
-1121  C→T 0.917 0.083 0.39  C→T 0.915 0.085 0.9
-964  G→A 0.505 0.496 0.15  G→A 0.591 0.409 1
-762  C→T 0.502 0.498 0.17  C→T 0.583 0.417 0.62
-716  T→G 0.513 0.487 0.17  T→G 0.581 0.419 0.42
-689  A→G 0.511 0.489 0.15  A→G 0.58 0.42 0.32
-666  G→T 0.511 0.49 0.12  G→T 0.598 0.402 0.73
-646  A→G 0.983 0.017 0.97  A→G 0.984 0.016 0.97
-633  G→A 0.513 0.487 0.15  G→A 0.588 0.412 0.72
-543  del→in 0.973 0.028 0.91  del→in 0.986 0.014 0.98
-536  in→del 0.977 0.023 0.94  in→del 0.972 0.028 0.92
-509  C→G 0.964 0.036 0.43  C→G 0.975 0.026 0.93
-486  A=C 0.5 0.5 0.09  A→C 0.582 0.418 0.5
-477  C→G 0.449 0.551 0.0039  C→G 0.547 0.453 0.63
-400  G→A 0.949 0.051 0.17  G→A 0.968 0.032 0.89
-391  G→A 0.946 0.054 0.27  G→A 0.968 0.032 0.89
-369  C→A 0.447 0.553 0.0049  C→A 0.544 0.457 0.68
-201  G→A 0.509 0.492 0.1  G→A 0.572 0.428 0.51
3’UTR           
  del→in 0.565 0.435 0.09  del→in 0.629 0.371 0.97
           
 
Major alleles (p) are listed to the left of the arrows while minor alleles are to the right of the 
arrows. HWE= Hardy Weinberg Equilibrium 
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Table III: SNP summary 
SNP 
Reference SNP 
No. or 
Surrounding Seq Calculation 
p-
value Allele Odds Ratio CI 
-
1305 CCACA*TTCAG X2=8.823 0.012 A 1.429 1.095-1.866 
-
1179 GCAGC*GAACT X2=8.863 0.012 G 1.466 1.124-1.912 
-
1155 ACATT*TTTTA Fisher's exact test 0.372    
-
1140 AGATT*TTA*T X2=2.157 0.34    
-
1138 T*CATCCATC Fisher's exact test 0.2    
-
1121 AGAGC*TCGCT Fisher's exact test 0.795    
-964 rs1632947 X2=7.453 0.024 A 1.42 1.079-1.870 
-762 rs1632946 X2=9.529 0.009 T 1.388 1.066-1.809 
-725 rs1233334 Fisher's exact test 0.478    
-716 rs2249863 X2=9.063 0.011 G 1.321 1.016-1.717 
-689 rs2735022 X2=10.108 0.006 G 1.325 1.020-1.722 
-666 TTACC*ATTAG X2=10.367 0.006 T 1.424 1.095-1.854 
-646 CATTC*GGGGT Fisher's exact test 1    
-633 rs1632944 X2=8.389 0.015 A 1.355 1.041-1.765 
-543 AGG*GGAAAA X2=2.088 0.149    
-536 GAAA*AAAAC X2=0.187 0.665    
-509 AATCC*AGGGC Fisher's exact test 0.687    
-486 rs1736933 X2=11.245 0.004 C 1.409 1.073-1.851 
-477 rs1736932 X2=16.646 0.0002 G 1.483 1.129-1.948 
-400 GACAG*GATTC Fisher's exact test 0.315    
-391 TCCGG*ATGAA Fisher's exact test 0.228    
-369 rs1632943 X2=15.647 0.0004 A 1.475 1.121-1.942 
-201 rs1631950 X2=8.553 0.014 G 1.291 0.988-1.686 
 
Reference SNP number or location, and results of chi-squared analysis or Fisher’s exact test for 
each SNP as well as odds ratios and confidence intervals for SNPs with p-values < 0.05.   
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Table IV: Haplotype 19 and Haplotype 13 case and control comparisons of haplotype counts 
Haplotype 19: chi-square 15.641, p=0.0004 
GAGCTAGGACCG     
  19,19 19,X X,X 
Cases 52 97 89 
Controls 58 126 49 
      
Haplotype 13: chi-square 9.701, p=0.00782 
AGATGGTACGAA    
  13,13 13,X X,X 
Cases 61 100 77 
Controls 33 114 86 
 
X represents any haplotype other than the haplotype of interest.
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 QuickTime™ and a
TIFF (LZW) decompressor
are needed to see this picture.
 
Figure 1: Haploview results 
Linkage disequilibrium (LD) between pairs of SNPs in the HLA-G promoter region for (a) cases 
and controls combined, (b) cases and (c) controls alone. Images were generated in Haploview, 
using only SNPs with minor allele frequencies >2%. Areas in shades of pink-dark red indicate 
strong LD (LOD>2, D’=1), blue indicates weak LD (LOD<2, D’=1) and white indicates no LD 
(LOD<2, D’<1). 
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SUPPLIMENTAL DATA 
 
We observed individuals with SNP frequencies below two percent, Table V. While they are rare, 
they are included for completeness.  
 
Table V: Counts of observed variants below two percent 
Location -1410 -1255 -922 -810 -779 
SNP CT GT CA CT CA 
No. samples 1 1 5 4 1 
Case/Cont 1/0 1/0 2/3 4/0 0/1 
Location -755 -483 -399 -361 -250 
SNP GA AG GA CT GA 
No. samples 2 6 2 1 1 
Case/Cont 0/2 3/3 1/1 1/0 1/0 
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We genotyped three SNPs in exon 2 and one insertion/deletion polymorphism in the 3’UTR in 
order to determine HLA-G alleles present in population. Four HLA-G alleles, *01041, *01013, 
*01012 and *01011, were found to be represented in our study. 
 
Table VI: Haplotypes, counts and HLA-G allele results from exon 1 and insertion/deletion 
genotyping. Haplotypes consist of the following locations in exon 2: 294, 374, 410 as well as the 
14 bp insertion or deletion in the 3’ UTR. 
Haplotype Counts HLA-G Allele 
AGCD 467 Other 
AACI 325 01041 
AACD 93 01013 and 01012 
AGCI 33 01011 
TGCI 22 Other 
TACI 2 Other 
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We wanted to examine haplotypes constructed using all 23 promoter region SNPs found in the 
1400 bp promoter region. 
 
Table VII: Haplotypes with more than one percent frequency in cases and controls. Numbers 1, 2 
and 3 correspond to SNP -725 which has three alleles: 1=C, 2=G, 3=T. 
Haplotype     Frequency 
AGGTACAT1GGTAADICCGGGAA 0.3230 
GAGAACGC1TAGAGDICACGGCG 0.3007 
AGAAACAT1GGTAADICCGGGAA 0.0945 
GAGAATGC2TAGAGDICACGGCG 0.0727 
GAGAACGC2TAGAGDICACGGCG 0.0620 
GAGAACGC1TAGAGDDCACGGCG 0.0234 
GGGAGCGC3TAGGGDIGAGAAAG 0.0141 
AGGTACAC1TAGAGDICACGGCG 0.0110 
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Table VIII: Haplotype number, haplotypes observed and counts in cases and controls combined 
using 12 SNPs in the promoter region. 
Haplotype 
No. Haplotype Count 
1 AGGTGGTACGAA 3 
2 AGACTAGGAGAG 2 
3 AGACTAGGACCG 11 
4 AGACTAGGCCCG 2 
5 AGACTATGCCCG 1 
6 AGACTATACCCG 1 
7 AGACGGGGACCG 1 
8 AGATGGGGCGAG 1 
9 AGATGGGAAGAA 1 
10 AGATGGGACGAA 3 
11 AGATGGTGCGAA 2 
12 AGATGGTACGAG 1 
13 AGATGGTACGAA 402 
14 GGGCTAGGAGAG 38 
15 GGGCTAGGACCG 4 
16 GGGTGGTACGAA 1 
17 GGATGGTACGAA 7 
18 GAGCTAGGAGCG 1 
19 GAGCTAGGACCG 443 
20 GAGCTAGGACCA 3 
21 GAGCTAGGCGAG 3 
22 GAGCTGTACGAA 1 
23 GAGCGAGGCGAG 1 
24 GAGTTAGGACCG 2 
25 GAGTGGGGAGAG 1 
26 GAGTGGGGCGAG 4 
27 GAGTGGTACGAA 1 
28 GAACTAGGACCG 1 
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We examined the full TFBSs, core and matrix sequences, with the SNPs that interrupt the 
binding site matrix. 
 
Table IX: Transcription factors and their binding site recognition sequences, which are 
interrupted by SNPs -1179, -1155, -762, -689, -486 and -201. Lowercase letters indicate matrix 
match, uppercase letters indicate core match. Bold letters signify location of SNP. 
Position Transcription factor binding site Factor name Factor prese
-1179 agcagCGGAActct Elk-1 If G, no
-1155 caTTGTTttata Foxd3 If G, no
-762 cagataCATTGtctgggaaagtga Comp1 If T, no
-689 accAACGGgc v-Myb If G, no
-486 tctggcaCCAAGctccctg Hnf-4 If C, no
-201 tgtatgGATTGgggaggccccgcg Comp1 If A, not
-201 tATGGAttgg Cdp Cr1 If A, not
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6.0  CONCLUSION 
It is reasonable to assume that there is more than one immunological cause of recurrent 
miscarriage. Using a select population of RSA cases and fertile controls, we were able to 
successfully investigating two aspects of immunology affecting pregnancy. Both studies 
provided us with data and rational conclusions, however during our efforts questions did arise 
that we were not able to answer. The MBL research we conducted was the largest MBL and RSA 
study to date. We were able to show that MBL genotypes, regardless of the number of 
miscarriages, did not affect pregnancy outcomes. What we were usable to establish however, was 
a direct link between MBL levels, infection and pregnancy loss. In order to confirm that low 
MBL plasma levels increase maternal and/or fetal infection, resulting in the miscarriages, we 
would have needed maternal exposure and infection rates. For future studies this information 
could possibly be gathered from socioeconomic background information, physician visits or self-
reported by the patient. The HLA-G project, while also successful, could be improved upon by 
further tests and analysis. We based our investigation on maternal samples and data. Careful 
examination of the literature however suggests that HLA-G is expressed on trophoblast cells, 
which are derived by the fetus. This being true, maternal SNP data is only partially responsible 
for HLA-G expression therefore adding paternal, or even fetal, HLA-G sequence analysis would 
be extremely beneficial to our study design in future experiments. 
 
During our twofold gene approach we did not find an association between molecularly 
deduced levels of plasma MBL in women and risk or number of RSA. Therefore, we do not 
consider maternal susceptibility to infection due to decreased plasma MBL levels to be a cause 
of RSA. We did generate 55 different HLA-G promoter region haplotypes, eight of which could 
account for more than 90% of the haplotypes found in cases and controls. Two of these, 
haplotype 13 and haplotype 19 were particularly interesting due differences seen in cases and 
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controls. Haploytpe 19 was significantly more frequent in controls while haplotype 13 was just 
the opposite, significantly more frequent in cases. The promoter region was discovered to be in 
LD across the 1400 bp region upstream of exon 1, and we were able to located 6 TFBS that are 
altered as a result of variation in the promoter region. Using the transcription factor data we 
discovered, we were able to incorporate it with data already known to create a map of the HLA-
G promoter region (Figure 3). As research in the area continues, we hope that this map will be 
useful to other investigations.  
 
 
Figure 2: HLA-G promoter region 
 
SNP and haplotype variation has proved to be a promising area of research in regards to 
MBL and HLA-G.  Continuing research will be advantageous due to the abundance of variation 
in genes associated with immunology as well as the likelihood that genetic variation has a role in 
maternal immune response to a fetus, and the fetal environment. 
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APPENDIX A 
ADDITIONAL ARTICLES OF INTEREST 
A class I antigen, HLA-G, expressed in human trophoblasts 
 
Population: First trimester villous cytotrophoblasts from four pooled individuals and four first 
trimester placental villi 
Methods: Immuno precipitation of methionine-labeled HLA-G+LCL.221 transferent cells with 
MAb W6/32 was run on a gel to identify an autoradiographic spot array, characteristic of the 
HLA-G alpha chain and distinct from the spot arrays of HLA-A, -B, -C, -E, -F 
Conclusion: Data shows a nonpolymprphic class I molecule, HLA-G, is expressed by 
cytotrophoblasts and suggests a function for these molecules in protecting the placenta from 
rejection. (Kovats et al. 1990) 
 
Characterization of a new HLA-G allele encoding a nonconservative amino acid substitution in 
the alpha3 domain (exon 4) and its relevance to certain complications in pregnancy 
 
Population: 22 fertile women, 22 fertile men, 106 healthy individuals, 31 women with PE, 19 
women who had experienced three or more spontaneous abortions and their partners 
Methods: Genotyped for polymorphism in exon 4 
Conclusion: Distribution of genotypes for all three groups was in accordance with HWE. No 
association with the HLA-G allele was found in pre-eclamptic, abortion or healthy populations. 
(Hviid et al. 2001) 
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HLA-G unique promoter region: functional implications 
 
Population: Transgenic HLA-G mouse models under the control of HLA-G promoter 
Methods: pHLA-G-il-EGFP transgene was microinjected into 39 viable embryos, 4 mice were 
backcrossed. Placental cDNA from embryos was amplified. 
Conclusion: PT-PCR demonstrated differential activity of HLA-G promoter in mouse transgenic 
placenta according to gestational stage. Once the placenta is fully formed, the functions of HLA-
G might not be crucial. (Solier et al. 2001) 
 
Altered phenotype of HLA-G expressing trophoblast and decidual natural killer cells in 
pathological pregnancies 
 
Population: 9 women with recurrent miscarriage, 5 women with ectopic tubal pregnancy and 11 
controls 
Methods: Designed to reveal HLA-G expression and NK cell distribution in tissues 
Conclusion: HLA-G protein is expressed at the cell surface of EVT cells in tissue from both 
recurrent miscarriage and ectopic pregnancies. In normal pregnancy there is a decrease and a 
morphological change in CD56+ NK cells upon interaction with HLA-G expressing 
trophoblasts. (Emmer et al. 2002) 
 
HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of 
pregnancy 
 
Population: 285 supernatants corresponding to 101 IVF procedures 
Methods: Soluable HLA-G levels were measured via ELISA 
Conclusion: Expression of HLA-G products in embryo cells is a mandatory, but not sufficient, 
prerequisite for the development of pregnancy. (Fuzzi et al. 2002) 
 
Expression of membrane-bound HLA-G at the maternal-fetal interface is not associated with 
pregnancy maintenance among patients with idiopathic recurrent pregnancy loss 
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Population: Trophoblast tissue from 47 women having dilation and curettage (D&C). Of these 
women, 30 had at least three first trimester pregnancy losses, 17 were elective terminations, 16 
had normal chromosomes and 14 presented with fetal trisomy 16. 
Methods: HLA-G protein expression at the maternal-fetal interface was studied. They studied 
immune-mediated RSA by using RSA patients with normal fetal chromosomes and patients with 
known chromosomal abnormalities. 
Conclusion: No significant differences were found in levels of HLA-G between groups of RSA 
patients. HLA-G expression is not a major immunological determinant of pregnancy 
maintenance among patients with idiopathic RSA. (Patel et al. 2003) 
 
Transcriptional status of HLA-G at the maternal-fetal interface in recurrent spontaneous abortion 
 
Population: 17 women with RSA, 25 controls 
Methods: HLA-G isoforms were expressed in terms of HLA-G transcript/ beta actin 
densitometric ratios 
Conclusion: Suggests that a lower relative transcription of HLA-G isoforms may contribute to 
the physiology of RSA. (Abbas et al. 2006) 
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APPENDIX B 
SNPPER CONSENSUS SEQUENCE 
SNPper Key: exons | CODING | Introns | SNP | 5'/3'  
1          2          3          4          5 
             1234567890 1234567890 1234567890 1234567890 1234567890 
 
 29,902,497  gcagttggcc tttaatatct tatgtgggtc tgcctagaaa ctaattgttt 
 29,902,547  tttatgttaa tcaggtttaa aaaatactaa gtattcctaa aaaatataca 
 29,902,597  ctccactcac atgtggatac ttcctaaaaa caggcagtgc gtgagcacta  
 29,902,647  gtgaggggca ttgtgactgc actgaacact tacaactgtg aggtgaataa 
 29,902,697  agtttgtgct ggctcctggt tgcaacatat agtaacatag tgtggtactt 
 29,902,747  tgtcttgagg agatgtcctg gactcacacg gaaacttagg gctacggaat 
 29,902,797  gaaggtaaat ttaaaataaa acaagcggga gtcacagata cactgtctgg  
 29,902,847  gaaagtgaaa cttaagagct ttgtgagtcg tgttgtaatg cttttagatg  
 29,902,897  catttatata ccaacaggcc aaagtcacat tttttaccga ttagattcct 
 29,902,947  gatcattcag gggttaccaa ggttatgcta cccactatag ttaataaaca   
 29,902,997  aaaagcaaac tggtctctat tctatctcat gcactcaggc acaacttttc 
 29,903,047  cagatttaag ggggaaaaaa aaccctgtct ttacacctac aatcccaggg 
 29,903,097  cgagctcact ctctggcaac aagctccctg gggtgatttt tcttctagaa  
 29,903,147  gagtacagga ggacaggcaa ggagtgggag gcagggagtc cagttcaggg 
 29,903,197  acagggattc cgggatgaaa agtgaaggga gagggccagg gaccttgccg   
 29,903,247  agggtttctc cctggtttct cagacagctc ctgggccaag actcagggag 
 29,903,297  acactgagac agaacgcttg gcacaagagt agcggggtca gggcgaagtc 
 29,903,347  ccagggcctc aagcgtggct ctcagggtct caggccccac aggcggtgta 
 29,903,397  tgggttgggg aggccccgcg ttggggattc tctcctcctt ctcctaacct   
 29,903,447  gtgtcgggtc cttcttcctg gatactcacc gggcggcccc agttctcact 
  
 29,903,497  cccattaggt gacaggtttt tagagaagcc aatcagcgtc gccgcggtcc Exon 1 
 29,903,547  tggttctaaa gtcctcgctc acccacccgg actcattctc cccagacgcc 
 29,903,597  aaggATGGTG GTCATGGCGC CCCGAACCCT CTTCCTGCTG CTCTCGGGGG    
 29,903,647  CCCTGACCCT GACCGAGACC TGGGCGGGTG AGTGCGGGGT CAGGAGGGAA Intron 1 
 29,903,697  ACAGCCCCTG CGCGGAGGAG GGAGGGGCCG GCCCGGCGGG GGCGCAGGAC   
 29,903,747  TCGGCAGCCG CGCCGGGAGG AGGGTCGGGC GGGTCTCAAC CCCTCCTCGC    
 29,903,797  CCCCAGGCTC CCACTCCATG AGGTATTTCA GCGCCGCCGT GTCCCGGCCC Exon 2 
 29,903,847  GGCCGCGGGG AGCCCCGCTT CATCGCCATG GGCTACGTGG ACGACACGCA   
 29,903,897  GTTCGTGCGG TTCGACAGCG ACTCGGCGTG TCCGAGGATG GAGCCGCGGG  
 29,903,947  CGCCGTGGGT GGAGCAGGAG GGGCCGGAGT ATTGGGAAGA GGAGACACGG  
 29,903,997  AACACCAAGG CCCACGCACA GACTGACAGA ATGAACCTGC AGACCCTGCG  
 29,904,047  CGGCTACTAC AACCAGAGCG AGGCCAGTGA GTAACTCCGG CCCAGGGAGC Intron 2  
 29,904,097  AGATCACGAC CCCCACCTCC ATGCCCCACG GACGGCCCGG GTACTCCCGA  
 29,904,147  GTCTCCGGGT CTGGGATCCA CCCCGAGGCC GCGGGACCCG CCCAGACCCT 
 29,904,197  CTACCTGGGA GAACCCCAAG GCGCCTTTAC CAAAATCCCC GCGGGTGGGT  
 29,904,247  CCGGGCGAGG GCGAGGCTCG GTGGGCGGGG CTGACCGAGG GGGTGGGGCC  
 29,904,297  AGGTTCTCAC ACCCTCCAGT GGATGATTGG CTGCGACCTG GGGTCCGACG Exon 3  
 29,904,347  GACGCCTCCT CCGCGGGTAT GAACAGTATG CCTACGATGG CAAGGATTAC  
 29,904,397  CTCGCCCTGA ACGAGGACCT GCGCTCCTGG ACCGCAGCGG ACACTGCGGC 
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 29,904,447  TCAGATCTCC AAGCGCAAGT GTGAGGCGGC CAATGTGGCT GAACAAAGGA 
 29,904,497  GAGCCTACCT GGAGGGCACG TGCGTGGAGT GGCTCCACAG ATACCTGGAG  
 29,904,547  AACGGGAAGG AGATGCTGCA GCGCGCGGGT ACCAGGGGCA GTGGGGCGCC Intron 3 
 29,904,597  TCCCTGATCT CCTGTAGACC TCTCAGCCTG GCCTAGCACA AGGAGAGGAG  
 29,904,647  GAAAATGGGA CCAACACTAG AATATCGCCC TCCCTCTGGT CCTGAGGGAG  
 29,904,697  AGGAATCCTC CTGGGTTTCC AGATCCTGTA CCAGAGAGTG ATTCTGAGGG 
 29,904,747  TCCGTCCTGC TCTCTGGGAC AATTAAGGGA TGAAGTCTCT GAGGGAGTGG  
 29,904,797  AGGGGAAGAC AATCCCTGGA AGACTGATCA GGGGTTCCCT TTGACCCCAC  
 29,904,847  AGCAGCCTTG GCACCAGGAC TTTTCCCCTC AGGCCTTGTT CTCTGCCTCA 
 29,904,897  CACTCAATGT GTGTGGGGGT CTGACTCCAG CTCCTCTGAG TCCCTTGGCC  
 29,904,947  TCCACTCAGG TCAGAACCGG AGGTCCCTGC TCCCCCGCTC AGAGACTAGA  
 29,904,997  ACTTTCCAAG GAATAGGAGA TTATCCCAGG TGCCCGTGTC CAGGCTGGTG 
 29,905,047  TCTGGGTTCT GTGCTCCCTT CCCCACCCCA GGTATCTGGT TCATTCTTAG 
 29,905,097  GATGGTCACA TCCAGGTGCT GCTGGAGTGT CCCATGAGAG ATGCAAAGTG 
 29,905,147  CTTGAATTTT CTGACTCTTC CTTTCAGACC CCCCCAAGAC ACACGTGACC Exon 4  
 29,905,197  CACCACCCTG TCTTTGACTA TGAGGCCACC CTGAGGTGCT GGGCCCTGGG 
 29,905,247  CTTCTACCCT GCGGAGATCA TACTGACCTG GCAGCGGGAT GGGGAGGACC 
 29,905,297  AGACCCAGGA CGTGGAGCTC GTGGAGACCA GGCCTGCAGG GGATGGAACC  
 29,905,347  TTCCAGAAGT GGGCAGCTGT GGTGGTGCCT TCTGGAGAGG AGCAGAGATA  
 29,905,397  CACGTGCCAT GTGCAGCATG AGGGGCTGCC GGAGCCCCTC ATGCTGAGAT  
 29,905,447  GGAGTAAGGA GGGAGATGGA GGCATCATGT CTGTTAGGGA AAGCAGGAGC Intron 4 
 29,905,497  CTCTCTGAAG ACCTTTAACA GGGTCGGTGG TGAGGGCTGG GGGTCAGAGA  
 29,905,547  CCCTCACCTT CACCTCCTTT CCCAGAGCAG TCTTCCCTGC CCACCATCCC Exon 5 
 29,905,597  CATCATGGGT ATCGTTGCTG GCCTGGTTGT CCTTGCAGCT GTAGTCACTG  
 29,905,647  GAGCTGCGGT CGCTGCTGTG CTGTGGAGAA AGAAGAGCTC AGGTAAGGAA Intron 5 
 29,905,697  GGGGTGACAA GTGGGGTCTG AGTTTTCTTG TCCCACTGGG GGTTTCAAGC 
 29,905,747  CCCAGGTAGA AGTGTGCCCT GCCTGGTTAC TGGGAAGCAC CATCCACACT 
 29,905,797  CATGGGCCTA CCCAGCCTGG GCCCTGTGTG CCAGCACCTT CTCTTTTGTA 
 29,905,847  AAGCACCTGT GACAATGAAG GACAGATTTA TTACCTTGAT GATTGTAGTG  
 29,905,897  ATGGGGACCT GATCCCAGTA ATCACAGGTC AGGAGAAGGT CCCTGGCTAA  
 29,905,947  GGACAGACCT TAGGAGGGCA GTTGGTCGAG GACCCACATC TGCTTTCCTT 
 29,905,997  GTTTTTCCTG ATCCCGCCCT GGGTCTGCAG TCACACATTT CTGGAAACTT  
 29,906,047  CTCGAGGGTC CAAGACTAGG AGGTTCCTCT AGGACCTCAT GGCCCTGCCA 
 29,906,097  CCTTTCTGGC CTCTCACAGG ACATTTTCTT CCCACAGATT GAaaaggagg Exon 6 
 29,906,147  gagctactct caggctgcaa gtaagtatga aggaggctga tccctgagat 
 29,906,197  ccttgggatc ttgtgtttgg gagcccatgg gggagctcac ccaccccaca 
 29,906,247  attcctcctc tggccacatc tcctgtggtc tctgaccagg tgctgttttt 
 29,906,297  gttctactct aggcagtgac agtgcccagg gctctaatgt gtctctcacg 
 29,906,347  gcttgtaaat gtgacacccc ggggggcctg atgtgtgtgg gttgttgagg 
 29,906,397  ggaacagggg acatagctgt gctatgaggt ttctttgact tcaatgtatt  
 29,906,447  gagcatgtga tgggctgttt aaagtgtcac ccctcactgt gactgatatg 
 29,906,497  aatttgttca tgaatatttt tctgtagtgt gaaacagctg ccctgtgtgg 
 29,906,547  gactgagtgg caagtccctt tgtgacttca agaaccctga ctcctctttg  
 29,906,597  tgcagagacc agcccacccc tgtgcccacc atgaccctct tcctcatgct 
 29,906,647  gaactgcatt ccttccccaa tcacctttcc tgttccagaa aaggggctgg 
 29,906,697  gatgtctccg tctctgtctc aaatttgtgg tccactgagc tataacttac  
 29,906,747  ttctgtatta aaattagaat ctgagtataa atttactttt tcaaattatt  
 29,906,797  tccaagagag attgatgggt taattaaagg agaagattcc tgaaatttga  
 29,906,847  gagacaaaat aaa 
  
 29,906,860  tggaagacat gagaactttc cacagtacac gtgtttcttg tgctgatttg 
 29,906,910  ttgcaggaga ggagagtaga tggggctgcg cccagtgggt gctcaggcca 
 29,906,960  ccatgaactt tatgtggtca ctgctcagct gggtcatctt tgctgctcca 
 29,907,010  ttgtccttgg cccttcagta gaaccttgtc ccaccaggac ctgtgatcac 
 29,907,060  atagacttgg atatcaccta ggatggtccc tacacgtaga agttcctgtg  
 29,907,110  ttatcagaag aaaaattttc agacccctac acctcttccc ctccttccag 
 29,907,160  gtctctttca attgtatttt ccatcttttt tttttttttt ttttttagat 
 29,907,210  ggagcctcac tcaggctgga gtgcagtggt gcaatctcaa ctcattgcaa  
 29,907,260  cctccacctc ccgggttcaa gcaattctcc tgtctcagcc tccctagtaa  
 29,907,310  ctgggagtac aggcacatgc cacaataccc agctaatttt ttgtattttt  
 29,907,360  agtaaagacg ggatttcacc atgttagcca ggatggtctt gatctcctga  
 29,907,410  ccttgtgatc tgcccgcctc tgcctcccaa agtgctggga ttacaggtgt 
 29,907,460  gagccaccat gcctggcttc cccaaccttc ttaaaggaag cagattctga  
 29,907,510  aacttcccga gaggagaggt cccagagttt ttcattgtag tttactttct 
 29,907,560  gttggaactc ctcttctgct ctctctccta ctcttcttcc tgccctgagt 
 29,907,610  tgtagtaatc ctattgctgg ctccaaacca aactcatgga tttgtaaagc 
 29,907,660  agagtctaat ttagattcat atgtggttgg ataattggag ccataagcct 
 29,907,710  tgggttatct ttcctcaaga gacaaatatg gttgtgtgct gcagtgtgca  
 72 
 29,907,760  ggaggattgg tgtgggagga gggagggagg gaggacacaa aagcagccct  
 29,907,810  ggtgagaaaa gcactggtgc atttatatcc acatgagata atattgttcc 
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APPENDIX C 
CONSENSUS SEQUENCE FOR TRANSFAC 
C.1 REFERENCE SEQUENCE: CASES, COMMON ALLELES 
 
GTAGCAGGACCACTATAGAGAGAACACTCATGTAGCAGGTCATGGAACAGTGCTAG
AGCCACAGTTCAGGAGTGAGAGGGTGGTGGGGATTAAGGGGAGAAGAGGGCCTGA
GGGATGAGAGGGACGGAGGGAAGGGCTGGAGGAGCAGGAGGTGAGGAAAAGGAG
CAGAGGAAAGAATTCCAAAGCAGCGGAACTCTTAGGTTTAAACACATTGTTTTATAG
ATTTTAATACATCCATCTACAGAGCCTCGCTGGGTGTTCTTTGCAGTTGGCCTTTAAT
ATCTTATGTGGGTCTGCCTAGAAACTAATTGTTTTTTATGTTAATCAGGTTTAAAAAA
TACTAAGTATTCCTAAAAAATATACACTCCACTCACATGTGGATACTTCCTAAAAAC
AGGCAGTGCGTGAGCACTAGTGAGGGGCATTGTGACTGCACTGAACACTTACAACT
GTGAGGTGAATAAAGTTTGTGCTGGCTCCTGGTTGCAACATATAGTAACATAGTGTG
GTACTTTTTCTTGAGGAGATGTCCTGGACTCACACGGAAACTTAGGGCTACGGAATG
AAGGTAAATTTAAAATAAAACAAGCGGGAGTCACAGATACACTGTCTGGGAAAGTG
AAACTTAAGAGCTTTGTGAGTCCTGTTGTAATGCTTTTAGATGCATTTATATACCAAC
AGGCCAAAGTCACATTTTTTACCGATTAGATTCCTGATCATTCAGGGGTTACCAAGG
TTATGCTACCCACTATAGTTAATAAACAAAAAGCAAACTGGTCTCTATTCTATCTCA
TGCACTCAGGCACAACTTTTCCAGATTTAAGGGGGAAAAAAAACCCTGTCTTTACAC
CTACAATCCCAGGGCGAGCTCACTCTCTGGCAACAAGCTCCGTGGGGTGATTTTTCT
TCTAGAAGAGTACAGGAGGACAGGCAAGGAGTGGGAGGCAGGGAGTCCAGTTCAG
GGACAGGGATTCCGGGATGAAAAGTGAAGGGAGAGGGACAGGGACCTTGCCGAGG
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GTTTCTCCCTGGTTTCTCAGACAGCTCCTGGGCCAAGACTCAGGGAGACACTGAGAC
AGAACGCTTGGCACAAGAGTAGCGGGGTCAGGGCGAAGTCCCAGGGCCTCAAGCGT
GGCTCTCAGGGTCTCAGGCCCCACAGGCGGTGTATGGGTTGGGGAGGCCCCGCGTT
GGGGATTCT 
 
C.2 REFERENCE SEQUENCE: CASES, MINOR ALLELES 
 
GTAGCAGGACCACTATAGAGAGAACACTCATGTAGCAGGTCATGGAACAGTGCTAG
AGCCACAATTCAGGAGTGAGAGGGTGGTGGGGATTAAGGGGAGAAGAGGGCCTGA
GGGATGAGAGGGACGGAGGGAAGGGCTGGAGGAGCAGGAGGTGAGGAAAAGGAG
CAGAGGAAAGAATTCCAAAGCAGCAGAACTCTTAGGTTTAAACACATTATTTTATAG
ATTTTATTGCATCCATCTACAGAGCTTCGCTGGGTGTTCTTTGCAGTTGGCCTTTAAT
ATCTTATGTGGGTCTGCCTAGAAACTAATTGTTTTTTATGTTAATCAGGTTTAAAAAA
TACTAAGTATTCCTAAAAAATATACACTCCACTCACATGTGGATACTTCCTAAAAAC
AGGCAGTGCATGAGCACTAGTGAGGGGCATTGTGACTGCACTGAACACTTACAACT
GTGAGGTGAATAAAGTTTGTGCTGGCTCCTGGTTGCAACATATAGTAACATAGTGTG
GTACTTTTTCTTGAGGAGATGTCCTGGACTCACACGGAAACTTAGGGCTACGGAATG
AAGGTAAATTTAAAATAAAACAAGCGGGAGTCACAGATACATTGTCTGGGAAAGTG
AAACTTAAGAGCTTTGTGAGTCGTGTTGTAAGGCTTTTAGATGCATTTATATACCAA
CGGGCCAAAGTCACATTTTTTACCTATTAGATTCCTGATCATTCAGGGGTTACCAAG
ATTATGCTACCCACTATAGTTAATAAACAAAAAGCAAACTGGTCTCTATTCTATCTC
ATGCACTCAGGCACAACTTTTCCAGATTTAAGGGGGAAAAAAAACCCTGTCTTTACA
CCTACAATCCCAGGGCGAGCTCACTCTCTGGCACCAAGCTCCCTGGGGTGATTTTTC
TTCTAGAAGAGTACAGGAGGACAGGCAAGGAGTGGGAGGCAGGGAGTCCAGTTCA
GGGACAGAGATTCCGGAATGAAAAGTGAAGGGAGAGGGCCAGGGACCTTGCCGAG
GGTTTCTCCCTGGTTTCTCAGACAGCTCCTGGGCCAAGACTCAGGGAGACACTGAGA
CAGAACGCTTGGCACAAGAGTAGCGGGGTCAGGGCGAAGTCCCAGGGCCTCAAGCG
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TGGCTCTCAGGGTCTCAGGCCCCACAGGCGGTGTATGGATTGGGGAGGCCCCGCGTT
GGGGATTCT 
 
C.3 REFERENCE SEQUENCE: CASES, MINOR ALLELES AND -725 T 
 
GTAGCAGGACCACTATAGAGAGAACACTCATGTAGCAGGTCATGGAACAGTGCTAG
AGCCACAATTCAGGAGTGAGAGGGTGGTGGGGATTAAGGGGAGAAGAGGGCCTGA
GGGATGAGAGGGACGGAGGGAAGGGCTGGAGGAGCAGGAGGTGAGGAAAAGGAG
CAGAGGAAAGAATTCCAAAGCAGCAGAACTCTTAGGTTTAAACACATTATTTTATAG
ATTTTATTGCATCCATCTACAGAGCTTCGCTGGGTGTTCTTTGCAGTTGGCCTTTAAT
ATCTTATGTGGGTCTGCCTAGAAACTAATTGTTTTTTATGTTAATCAGGTTTAAAAAA
TACTAAGTATTCCTAAAAAATATACACTCCACTCACATGTGGATACTTCCTAAAAAC
AGGCAGTGCATGAGCACTAGTGAGGGGCATTGTGACTGCACTGAACACTTACAACT
GTGAGGTGAATAAAGTTTGTGCTGGCTCCTGGTTGCAACATATAGTAACATAGTGTG
GTACTTTTTCTTGAGGAGATGTCCTGGACTCACACGGAAACTTAGGGCTACGGAATG
AAGGTAAATTTAAAATAAAACAAGCGGGAGTCACAGATACATTGTCTGGGAAAGTG
AAACTTAAGAGCTTTGTGAGTCTTGTTGTAAGGCTTTTAGATGCATTTATATACCAAC
GGGCCAAAGTCACATTTTTTACCTATTAGATTCCTGATCATTCAGGGGTTACCAAGA
TTATGCTACCCACTATAGTTAATAAACAAAAAGCAAACTGGTCTCTATTCTATCTCA
TGCACTCAGGCACAACTTTTCCAGATTTAAGGGGGAAAAAAAACCCTGTCTTTACAC
CTACAATCCCAGGGCGAGCTCACTCTCTGGCACCAAGCTCCCTGGGGTGATTTTTCT
TCTAGAAGAGTACAGGAGGACAGGCAAGGAGTGGGAGGCAGGGAGTCCAGTTCAG
GGACAGAGATTCCGGAATGAAAAGTGAAGGGAGAGGGCCAGGGACCTTGCCGAGG
GTTTCTCCCTGGTTTCTCAGACAGCTCCTGGGCCAAGACTCAGGGAGACACTGAGAC
AGAACGCTTGGCACAAGAGTAGCGGGGTCAGGGCGAAGTCCCAGGGCCTCAAGCGT
GGCTCTCAGGGTCTCAGGCCCCACAGGCGGTGTATGGATTGGGGAGGCCCCGCGTT
GGGGATTCT 
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APPENDIX D 
EXON 2 AND 3’ UNTRANSLATED REGION HAPLOTYPES 
Index Haplotype Count 
1 CAGCTGD 456 
2 TAACCGI 284 
3 TAACCGD 88 
4 CAACCGI 40 
5 CAGCCGI 24 
6 CTGCCTI 21 
7 TAGCTGD 6 
8 CAACTGD 5 
9 CAGCCGD 4 
10 TAGCTGI 4 
11 CAGCTGI 3 
12 CTATTI 2 
13 TAGCGI 2 
14 CTGCGI 1 
15 TAGTTD 1 
16 TAATGI 1 
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APPENDIX E 
EXON 2 AND 3’ UNTRANSLATED REGION HAPLOTYPES, SPECIFIC TO 
PUBLISHED NOMENCLATURE 
Haplotype Counts HLA-G Allele 
AGCD 467 Other 
AACI 325 01041 
AACD 93 01013 and 01012 
AGCI 33 01011 
TGCI 22 Other 
TACI 2 Other 
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APPENDIX F 
PROMOTER REGION HAPLOTYPES 
Index Haplotype Count 
1 AGGTACAT1GGTAADICCGGGAA 314 
2 GAGAACGC1TAGAGDICACGGCG 290 
3 AGAAACAT1GGTAADICCGGGAA 84 
4 GAGAATGC2TAGAGDICACGGCG 71 
5 GAGAACGC2TAGAGDICACGGCG 52 
6 GAGAACGC1TAGAGDDCACGGCG 21 
7 GGGAGCGC3TAGGGDIGAGAAAG 13 
8 AGGTACAC1TAGAGDICACGGCG 10 
9 GGGAGCGC3TAGAGIICAGAAAG 8 
10 GGGAGCGC3TAGAGIIGAGAAAG 8 
11 GGGTACAT1GGTAADICCGGGAA 7 
12 GAGAATGC1TAGAGDICACGGCG 5 
13 GGGAGCGC3TAGAGDIGAGAAAG 4 
14 GAGAACGT1GGGAGDICCGGGAG 4 
15 AGGTACAT1GGGAADICCGGGAA 3 
16 GAGAACGC1TAGAGDICCGGGAG 3 
17 AGGTACAC3TAGAGIIGAGAAAG 2 
18 AGGTACAT1GGTAGDICCGGGAA 2 
19 AGAAACGT1GGTAADICCGGGAA 2 
20 GGGAACGC1TAGAGDICACGGCG 2 
21 GAGAACGC1TAGAGDICACGGCA 2 
22 GAGAACGT1GGTAADICCGGGAA 2 
23 AGGAACGC2TAGAGDICACGGCG 1 
24 AGGAACAC1TAGAADICCCGGCG 1 
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Index Haplotype Count 
25 AGGAACAT1GGGAGDICCGGGAA 1 
26 AGGAACAT1GGTAADICCGGGAA 1 
27 AGGTACGT1GGTAADICCGGGAA 1 
28 AGGTACAC1TAGAGDICCCGGCG 1 
29 AGGTACAC2TAGAGDICACGGCG 1 
30 AGGTACAT1GGTAADIGCGGGAG 1 
31 AGGTATAT1GGTAADICCGGGAA 1 
32 AGGTGCAT1GGTAADICCGGGAA 1 
33 AGAAACAC1TATAGDICCCGGCG 1 
34 AGAAACAC1GGGAGDICCCGGCG 1 
35 AGAAACAT1GGGAADICAGGGAA 1 
36 AAGAACGC2TAGAGDICACGGCG 1 
37 GGGAACGC3TAGGGDIGAGAAAG 1 
38 GGGAATGC1TAGAGDICACGGCG 1 
39 GGGAGCGC2TAGAGIICAGAAAG 1 
40 GGGAGCGC3TAGAGDICAGAAAG 1 
41 GGGAGCGC3TAGAGDIGAGGAAG 1 
42 GGGAGCGC3TAGGGIIGAGAAAG 1 
43 GGGAGCGT1GGTAADICCGGGAA 1 
44 GGAAGCGC3TAGAGDIGAGAAAG 1 
45 GAGAACGC1TAGAGDICACAACG 1 
46 GAGAACGC1TAGAGDDCAGGGCG 1 
47 GAGAACGC1TGTAADICCGGGAA 1 
48 GAGAACGC1GAGAGDICCGGGAG 1 
49 GAGAACGT1TAGAGDICACGGCG 1 
50 GAGAACGT1TAGAGDDCACGGCG 1 
51 GAGAACGT1GGGAGDICAGGGAA 1 
52 GAGAACAC1TAGAGDICACGGCG 1 
53 GAGAATGC2TAGAGDICACAGCG 1 
54 GAGAATGC2TAGAGDICACAACG 1 
55 GAGTATGC2TAGAGDICACGGCG 1 
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APPENDIX G 
EXON 2 AND 3’ UNTRANSLATED REGION HAPLOTYPE FREQUENCIES 
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APPENDIX H 
PROMOTER REGION HAPLOTYPE FREQUENCIES 
Index   E(freq) SE 
Control 
Freq SE(Control) 
Case 
Freq SE(Case) 
1 AGGAACGC1TAGAGDICACGGCG 0.00017 0.000458 0.000064 0.000365 0.000273 0.000707 
2 AGGAACGC2TAGAGDICACGGCG 0.000464 0.000693 0.000193 0.000614 0.000729 0.001 
3 AGGAACGT1GGTAADICCGGGAA 0.000011 0.000106 0 0 0.000021 0.000209 
4 AGGAACAT1GGTAADICCGGGAA 0.001146 0.000336 0.000107 0.000467 0.002164 0.000465 
5 AGGAGCGC3TAGAGDIGAGGAAG 0.000064 0.000252 0 0 0.000126 0.000498 
6 AGGAGCGC3TAGGGDIGAGAAAG 0.000021 0.000148 0 0 0.000042 0.000294 
7 AGGTACGC1TAGAGDDCACGGCG 0.000032 0.000181 0.000021 0.000213 0.000042 0.000294 
8 AGGTACGC3TAGAGDIGAGGAAG 0.000021 0.000148 0 0 0.000042 0.000294 
9 AGGTACGT1GGTAADICCGGGAA 0.001168 0.00038 0.000129 0.000588 0.002185 0.000411 
10 AGGTACAC1TAGAGDICACGGCG 0.010951 0.001448 0.010924 0.002179 0.010976 0.001418 
11 AGGTACAC1TAGAGDICACGGCA 0.000021 0.000148 0.000043 0.0003 0 0.000002 
12 AGGTACAC1TAGAGDICCCGGCG 0.001253 0.00042 0.000064 0.000365 0.002416 0.000751 
13 AGGTACAC1TAGAGDDCACGGCG 0.000027 0.000174 0.000032 0.000261 0.000023 0.000218 
14 AGGTACAC1TAGAADICACGGCG 0.000042 0.000208 0 0.000008 0.000084 0.000411 
15 AGGTACAC1TAGAADICCCGGCG 0.000075 0.000271 0 0 0.000148 0.000538 
16 AGGTACAC1GGGAGDICCCGGCG 0.000053 0.000261 0.000086 0.000421 0.000021 0.000209 
17 AGGTACAC1GGGAADICCCGGAA 0.000426 0.000649 0.000711 0.00101 0.000147 0.000536 
18 AGGTACAC2TAGAGDICACGGCG 0.001658 0.000681 0.001164 0.001326 0.002143 0.000294 
19 AGGTACAC2TAGAGDICACAGCG 0.000032 0.000181 0 0 0.000063 0.000358 
20 AGGTACAC3TAGAGDIGAGGAAG 0.000104 0.000315 0 0 0.000204 0.000622 
21 AGGTACAC3TAGAGIICAGAAAG 0.000074 0.000292 0.000021 0.000213 0.000126 0.000545 
22 AGGTACAC3TAGAGIIGAGAAAG 0.001964 0.000571 0.000064 0.000365 0.003824 0.00106 
23 AGGTACAC3TAGGGDIGAGAAAG 0.000064 0.000293 0.000064 0.000365 0.000063 0.000358 
24 AGGTACAT1TAGAGDICACGGCG 0.000021 0.000148 0.000043 0.0003 0 0 
25 AGGTACAT1TAGAADICCCGGCG 0.000021 0.000148 0 0 0.000042 0.000294 
26 AGGTACAT1TGTAADICCCGGAA 0.000032 0.000181 0 0 0.000063 0.000358 
27 AGGTACAT1TGTAADICCCGGCG 0.000042 0.000256 0.000021 0.000213 0.000063 0.000358 
28 AGGTACAT1GGGAGDICAGGGAA 0.000032 0.000229 0.000021 0.000213 0.000042 0.000294 
29 AGGTACAT1GGGAGDICACGGCG 0.000032 0.000181 0.000043 0.0003 0.000021 0.000209 
30 AGGTACAT1GGGAADICCGGGAA 0.003673 0.000737 0.00663 0.000994 0.000777 0.001018 
31 AGGTACAT1GGTAGDICCGGGAA 0.00193 0.000658 0.00015 0.000547 0.003672 0.001186 
 82 
32 AGGTACAT1GGTAADICACGGCG 0.000032 0.000181 0.000064 0.000365 0 0 
33 AGGTACAT1GGTAADICCGGGAG 0.000053 0.000231 0.000064 0.000365 0.000042 0.000294 
34 AGGTACAT1GGTAADICCGGGAA 0.32301 0.003352 0.299263 0.004601 0.346266 0.004207 
35 AGGTACAT1GGTAADICCGGGCG 0.000032 0.000223 0.000043 0.000395 0.000021 0.000209 
36 AGGTACAT1GGTAADICCGAGAA 0.00035 0.000499 0 0 0.000694 0.000988 
37 AGGTACAT1GGTAADIGCGGGAG 0.001125 0.000264 0.000128 0.000533 0.002101 0.000002 
38 AGGTACAT1GGTAAIICCGGGAA 0.00035 0.000499 0 0 0.000693 0.000988 
39 AGGTACAT1GGTGADICCGGGAA 0.00017 0.000437 0.000043 0.0003 0.000295 0.000729 
40 AGGTATAT1GGTAADICCGGGAA 0.002675 0.001668 0.001249 0.001486 0.004071 0.002493 
41 AGGTGCAT1GGTAADICCGGGAA 0.001115 0.000262 0.002189 0.0003 0.000063 0.000358 
42 AGAAACGT1GGTAADICCGGGAA 0.002261 0.000381 0.00236 0.000696 0.002164 0.000358 
43 AGAAACAC1TAGAGDICACGGAA 0.000021 0.000149 0.000043 0.000301 0 0 
44 AGAAACAC1TAGAGDICACGGCG 0.000848 0.00115 0.001414 0.001904 0.000294 0.000776 
45 AGAAACAC1TAGAGDICCCGGCG 0.000437 0.000579 0.000818 0.001042 0.000063 0.000359 
46 AGAAACAC1TAGAADICACGGCG 0.000021 0.000149 0.000043 0.000301 0 0 
47 AGAAACAC1TAGAADICCCGGCG 0.000032 0.000181 0 0 0.000063 0.000359 
48 AGAAACAC1TATAGDICACGGCG 0.000032 0.000181 0.000065 0.000367 0 0 
49 AGAAACAC1TATAGDICCCGGCG 0.00054 0.000707 0.000941 0.001148 0.000146 0.000535 
50 AGAAACAC1TATAADICCCGGCG 0.000011 0.000106 0 0 0.000022 0.000212 
51 AGAAACAC1GGGAGDICCCGGAG 0.000032 0.000181 0.000064 0.000366 0 0 
52 AGAAACAC1GGGAGDICCCGGCG 0.000446 0.000647 0.000816 0.001126 0.000084 0.000412 
53 AGAAACAC1GGGAADICCCGGAA 0.000189 0.000407 0.000383 0.000822 0 0.000018 
54 AGAAACAC1GGGAADICCCGGCG 0.000053 0.000231 0.000107 0.000468 0 0 
55 AGAAACAC3TAGGGDIGAGAAAG 0.000021 0.000148 0.000021 0.000213 0.000021 0.000209 
56 AGAAACAT1GGGAGDICAGGGAA 0.000011 0.000106 0.000021 0.000214 0 0 
57 AGAAACAT1GGGAADICAGGGAA 0.001138 0.0005 0.002172 0.000863 0.000126 0.0005 
58 AGAAACAT1GGTAGDICCGGGAA 0.000021 0.000149 0 0 0.000042 0.000294 
59 AGAAACAT1GGTAADICCGGGAA 0.094545 0.002313 0.078391 0.003383 0.110359 0.003001 
60 AGAAACAT1GGTAADICCGAGAA 0.000127 0.000376 0.000021 0.000213 0.000231 0.000657 
61 AGAAGCGC3TAGAGDICAGAAAG 0.000042 0.000208 0 0 0.000084 0.000411 
62 AGAAGCGC3TAGAGDIGAGGAAG 0.000329 0.000744 0 0 0.000651 0.001473 
63 AGAAGCGC3TAGAGDIGAGAAAG 0.000021 0.000148 0 0 0.000042 0.000294 
64 AGAAGCGC3TAGAGIICAGAAAG 0.000042 0.000208 0 0 0.000084 0.000411 
65 AGAAGCGC3TAGAGIIGAGAAAG 0.000073 0.000269 0 0 0.000145 0.000532 
66 AGAAGCGC3TAGGGDIGAGAAAG 0.000106 0.000352 0 0 0.000209 0.000696 
67 AGAAGCGT1GGTAADICCGGGAA 0.000042 0.000208 0 0 0.000084 0.000412 
68 AAGAACGC1TAGAGDICACGGCG 0.000363 0.000557 0.000043 0.0003 0.000677 0.001004 
69 AAGAACGC1TAGAGDDCACGGCG 0.000021 0.000148 0.000043 0.0003 0 0.000001 
70 AAGAACGC2TAGAGDICACGGCG 0.000298 0.00063 0.000022 0.000214 0.000569 0.001167 
71 GGGAACGC1TAGAGDICACGGCG 0.002293 0.000491 0.002403 0.000911 0.002185 0.000412 
72 GGGAACGC1TAGAGIICACGGCG 0.000265 0.00046 0.000536 0.000929 0 0 
73 GGGAACGC2TAGAGDICACGGCG 0.000284 0.000549 0.000574 0.00111 0 0 
74 GGGAACGC2TAGAGIICAGAAAG 0.000021 0.000148 0.000043 0.0003 0 0 
75 GGGAACGC2TAGAGIICACGGCG 0.000106 0.000318 0.000215 0.000644 0 0 
76 GGGAACGC3TAGGGDIGAGAAAG 0.001178 0.000468 0.002254 0.000732 0.000126 0.000499 
77 GGGAACGC3TAGGGDDGAGAAAG 0.000032 0.000235 0.000043 0.0003 0.000021 0.000209 
78 GGGAATGC1TAGAGDICACGGCG 0.001146 0.00031 0.000171 0.000628 0.002101 0.000007 
79 GGGAATGC2TAGAGDICACGGCG 0.000202 0.000443 0.000408 0.000895 0 0 
80 GGGAGCGC1TAGAGIICAGAAAG 0.000064 0.000252 0.000129 0.00051 0 0 
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81 GGGAGCGC1TAGAGIIGAGAAAG 0.000034 0.000186 0.000068 0.000376 0 0 
82 GGGAGCGC2TAGAGDICACGGCG 0.000085 0.000325 0.000172 0.000657 0 0 
83 GGGAGCGC2TAGAGIICAGAAAG 0.000295 0.000499 0.000598 0.001008 0 0 
84 GGGAGCGC2TAGAGIICACGGCG 0.000053 0.000231 0.000107 0.000467 0 0 
85 GGGAGCGC2TAGAGIIGAGAAAG 0.000212 0.000425 0.00043 0.000859 0 0 
86 GGGAGCGC3TAGAGDICAGAAAG 0.001221 0.000417 0.000021 0.000213 0.002395 0.000806 
87 GGGAGCGC3TAGAGDIGAGGAAG 0.000682 0.000653 0.000064 0.000366 0.001288 0.001183 
88 GGGAGCGC3TAGAGDIGAGAAAG 0.003185 0.000684 0.002082 0.000564 0.004265 0.001178 
89 GGGAGCGC3TAGAGIICAGAAAG 0.009101 0.000872 0.004963 0.001009 0.013151 0.001358 
90 GGGAGCGC3TAGAGIIGAGAAAG 0.008206 0.000823 0.006867 0.000873 0.009517 0.001399 
91 GGGAGCGC3TAGGGDIGAGAAAG 0.014062 0.000981 0.013136 0.001313 0.01497 0.001383 
92 GGGAGCGC3TAGGGIIGAGAAAG 0.000616 0.000622 0.000021 0.000214 0.001197 0.001198 
93 GGGAGCGT1GGTAADICCGGGAA 0.00121 0.000443 0.000279 0.000823 0.002122 0.000363 
94 GGGAGTGC3TAGAGDIGAGAAAG 0.000138 0.000357 0 0 0.000273 0.000707 
95 GGGTACAC3TAGAGIIGAGAAAG 0.00018 0.00057 0.000021 0.000213 0.000336 0.001032 
96 GGGTACAT1GGTAADICCGGGAA 0.007565 0.001042 0.012631 0.001824 0.002605 0.001036 
97 GGAAGCGC3TAGAGDICAGAAAG 0.000011 0.000106 0 0 0.000021 0.000209 
98 GGAAGCGC3TAGAGDIGAGGAAG 0.000021 0.000205 0 0 0.000042 0.000404 
99 GGAAGCGC3TAGAGDIGAGAAAG 0.000021 0.000149 0 0 0.000042 0.000295 
100 GGAAGCGC3TAGAGIICAGAAAG 0.000106 0.000352 0 0 0.000211 0.000698 
101 GGAAGCGC3TAGAGIIGAGAAAG 0.00017 0.000417 0 0 0.000336 0.000825 
102 GGAAGCGC3TAGGGDIGAGAAAG 0.000277 0.00051 0.000064 0.000366 0.000486 0.000907 
103 GAGAACGC1TAGAGDICAGGGAA 0.000021 0.000187 0.000043 0.000373 0 0 
104 GAGAACGC1TAGAGDICACGGAG 0.000032 0.000186 0.000021 0.000213 0.000042 0.000294 
105 GAGAACGC1TAGAGDICACGGAA 0.000064 0.000292 0.000128 0.00059 0 0 
106 GAGAACGC1TAGAGDICACGGCG 0.300681 0.003328 0.334082 0.005133 0.267989 0.003732 
107 GAGAACGC1TAGAGDICACGGCA 0.002399 0.000599 0.00266 0.001177 0.002143 0.000294 
108 GAGAACGC1TAGAGDICACAACG 0.001093 0.000181 0.00221 0.000366 0 0 
109 GAGAACGC1TAGAGDICCGGGAG 0.003641 0.000638 0.000772 0.001135 0.006449 0.000535 
110 GAGAACGC1TAGAGDICCGGGAA 0.000032 0.000181 0.000064 0.000365 0 0 
111 GAGAACGC1TAGAGDICCCGGCG 0.000106 0.000329 0.000065 0.000367 0.000147 0.000535 
112 GAGAACGC1TAGAGDIGACGGCG 0.000021 0.000154 0.000043 0.00031 0 0 
113 GAGAACGC1TAGAGDDCAGGGCG 0.001125 0.000252 0.002231 0.00042 0.000042 0.000295 
114 GAGAACGC1TAGAGDDCACGGCG 0.023354 0.001292 0.025344 0.002164 0.021405 0.001164 
115 GAGAACGC1TAGAADICACGGCG 0.000361 0.000525 0.000043 0.0003 0.000672 0.00098 
116 GAGAACGC1TAGAADICCCGGAA 0.000128 0.000377 0.000021 0.000213 0.000232 0.000658 
117 GAGAACGC1TAGAADICCCGGCG 0.000106 0.000318 0 0 0.000209 0.000629 
118 GAGAACGC1TAGAADDCACGGCG 0.000021 0.000149 0 0 0.000042 0.000294 
119 GAGAACGC1TATAGDICACGGCG 0.000405 0.000516 0.000818 0.001042 0 0.000005 
120 GAGAACGC1TATAGDICCCGGAG 0.000021 0.000149 0.000043 0.0003 0 0 
121 GAGAACGC1TATAGDICCCGGCG 0.00017 0.000417 0.000322 0.000766 0.000021 0.00021 
122 GAGAACGC1TATAADICCCGGAA 0.000033 0.000183 0 0 0.000064 0.000362 
123 GAGAACGC1TATAADICCCGGCG 0.000032 0.000181 0 0 0.000063 0.000358 
124 GAGAACGC1TGGAGDICAGGGAA 0.000403 0.000577 0.000771 0.001073 0.000042 0.000294 
125 GAGAACGC1TGGAGDICAGGGCA 0.000127 0.000376 0.000257 0.00076 0 0 
126 GAGAACGC1TGTAADICCGGGAA 0.000577 0.000626 0.001166 0.001265 0 0 
127 GAGAACGC1TGTAADICCCGGAA 0.000094 0.000302 0 0 0.000187 0.000598 
128 GAGAACGC1GAGAGDICACGGCG 0.000021 0.000149 0.000021 0.000213 0.000021 0.000209 
129 GAGAACGC1GAGAGDICCGGGAG 0.00111 0.000513 0.002039 0.000767 0.0002 0.000617 
 84 
130 GAGAACGC1GAGAGDICCGGGAA 0.000021 0.000149 0.000043 0.0003 0 0 
131 GAGAACGC1GAGAGDICCCGGCG 0.000095 0.000383 0.000171 0.000656 0.000021 0.000209 
132 GAGAACGC1GGGAGDICAGGGAA 0.000095 0.000427 0.000129 0.000593 0.000063 0.000358 
133 GAGAACGC1GGGAGDICCGGGAG 0.000021 0.000149 0.000043 0.0003 0 0 
134 GAGAACGC2TAGAGDICACGGCG 0.06202 0.002413 0.070509 0.00417 0.05371 0.002445 
135 GAGAACGC2TAGAGDICACAGCG 0.000287 0.000528 0.000064 0.000365 0.000504 0.000897 
136 GAGAACGC3TAGAGDIGAGGAAG 0.000085 0.000288 0 0 0.000167 0.000569 
137 GAGAACGC3TAGGGDIGAGAAAG 0.000032 0.000228 0.000021 0.000213 0.000042 0.000294 
138 GAGAACGT1TAGAGDICACGGCG 0.001116 0.000234 0.000088 0.000426 0.002122 0.000209 
139 GAGAACGT1TAGAGDDCACGGCG 0.001093 0.000181 0 0.000007 0.002164 0.000358 
140 GAGAACGT1GGGAGDICAGGGAA 0.000637 0.000728 0.001204 0.001334 0.000084 0.000412 
141 GAGAACGT1GGGAGDICCGGGAG 0.003647 0.000814 0.006825 0.001311 0.000536 0.000939 
142 GAGAACGT1GGGAADICAGGGAA 0.000061 0.000302 0.000102 0.000548 0.000021 0.000209 
143 GAGAACGT1GGGAADICCGGGAA 0.000032 0.000221 0.000043 0.000389 0.000021 0.000209 
144 GAGAACGT1GGTAGDICCGGGAA 0.000331 0.000766 0.000236 0.000723 0.000425 0.001064 
145 GAGAACGT1GGTAADICCGGGAA 0.0027 0.000754 0.000888 0.001311 0.004474 0.000817 
146 GAGAACAC1TAGAGDICACGGCG 0.001136 0.000483 0.000193 0.000647 0.002059 0.000662 
147 GAGAACAT1GGTAGDICCGGGAA 0.000021 0.000148 0 0 0.000042 0.000294 
148 GAGAACAT1GGTAADICCGGGAA 0.000103 0.000359 0.000037 0.00028 0.000168 0.000572 
149 GAGAATGC1TAGAGDICACGGCG 0.004097 0.001804 0.005406 0.002372 0.002816 0.002198 
150 GAGAATGC1TGTAADICCGGGAA 0.000612 0.000661 0.001236 0.001336 0 0 
151 GAGAATGC1TGTAADICCCGGAA 0.000011 0.000107 0 0.000001 0.000022 0.000213 
152 GAGAATGC2TAGAGDICACGGCG 0.072669 0.001866 0.076903 0.003338 0.068525 0.001872 
153 GAGAATGC2TAGAGDICACAGCG 0.000255 0.000478 0.000021 0.000213 0.000484 0.000884 
154 GAGAATGC2TAGAGDICACAACG 0.001093 0.000181 0.000064 0.000366 0.002101 0.000017 
155 GAGAGCGC3TAGAGDIGAGGAAG 0.000021 0.000149 0 0 0.000042 0.000294 
156 GAGAGCGC3TAGAGDIGAGAAAG 0.000042 0.000208 0.000085 0.00042 0 0 
157 GAGTACGC2TAGAGDICACGGCG 0.000457 0.000547 0.000923 0.001105 0 0 
158 GAGTATGC2TAGAGDICACGGCG 0.000647 0.000579 0.001287 0.001135 0.000021 0.000209 
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APPENDIX I 
HAPLOTYPE DATA: CASES AND CONTROLS 
I.1  
SNP Position ObsHET PredHET HWpval %Geno Minor AF 
-1305 0.471 0.497 0.314 94.2 0.459 
-1179 0.454 0.5 0.068 93.3 0.49 
-1155 0.186 0.18 0.743 94.2 0.1 
-1140 0.436 0.461 0.304 93.6 0.36 
-1138 0.069 0.075 0.251 93.6 0.039 
-1121 0.16 0.151 0.394 94 0.083 
-964 0.462 0.497 0.194 88.7 0.459 
-762 0.477 0.496 0.46 98 0.458 
-716 0.481 0.496 0.57 99.1 0.455 
-689 0.483 0.496 0.636 99.6 0.455 
-666 0.469 0.494 0.302 98.9 0.447 
-646 0.033 0.033 1 99.8 0.017 
-633 0.468 0.495 0.284 98 0.451 
-543 0.04 0.04 1 98.9 0.02 
-536 0.052 0.05 1 98.9 0.026 
-509 0.056 0.059 0.668 98.7 0.03 
-486 0.473 0.497 0.349 98.4 0.459 
-477 0.458 0.5 0.091 97.8 0.497 
-400 0.074 0.08 0.336 98.9 0.041 
-391 0.078 0.083 0.397 99.1 0.044 
-369 0.455 0.5 0.071 96 0.495 
-201 0.476 0.497 0.411 96 0.462 
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I.2  
L1 L2 D' LOD r^2 CI low Chi Dist 
-1305 -1179 1 137.77 0.81 0.98 1 126 
-1305 -1155 1 17.7 0.13 0.9 1 150 
-1305 -1140 0.95 89.52 0.61 0.91 0.98 165 
-1305 -1138 0.85 2.41 0.03 0.4 0.96 167 
-1305 -1121 1 10.17 0.08 0.83 1 184 
-1305 -964 0.98 165.16 0.96 0.96 1 341 
-1305 -762 0.94 140.13 0.87 0.9 0.96 543 
-1305 -716 0.94 145.15 0.88 0.91 0.97 589 
-1305 -689 0.93 143.26 0.87 0.9 0.96 616 
-1305 -666 0.95 142.98 0.87 0.92 0.98 639 
-1305 -633 0.96 148.08 0.89 0.92 0.98 672 
-1305 -536 1 3.97 0.02 0.62 1 769 
-1305 -509 1 2.96 0.03 0.51 1 796 
-1305 -486 0.93 138.73 0.85 0.89 0.96 819 
-1305 -477 0.92 107.79 0.72 0.87 0.95 828 
-1305 -400 1 3.11 0.04 0.53 1 905 
-1305 -391 1 3.4 0.04 0.56 1 914 
-1305 -369 0.94 115.47 0.76 0.9 0.97 936 
-1305 -201 0.94 141.05 0.88 0.91 0.97 1104 
-1179 -1155 1 13.74 0.11 0.88 1 24 
-1179 -1140 0.99 84.26 0.55 0.95 1 39 
-1179 -1138 1 6.69 0.04 0.75 1 41 
-1179 -1121 0.9 8.82 0.08 0.71 0.97 58 
-1179 -964 0.99 131.34 0.82 0.96 1 215 
-1179 -762 0.97 117.68 0.76 0.93 0.99 417 
-1179 -716 0.98 121.61 0.77 0.94 1 463 
-1179 -689 0.97 119.03 0.76 0.93 0.99 490 
-1179 -666 0.99 122.54 0.76 0.96 1 513 
-1179 -633 0.99 126.47 0.78 0.96 1 546 
-1179 -536 1 4.22 0.03 0.63 1 643 
-1179 -509 1 4.14 0.03 0.63 1 670 
-1179 -486 0.95 114.76 0.74 0.91 0.98 693 
-1179 -477 0.95 144.41 0.87 0.92 0.98 702 
-1179 -400 1 6.33 0.04 0.74 1 779 
-1179 -391 1 6.31 0.04 0.74 1 788 
-1179 -369 0.98 155.75 0.92 0.95 1 810 
-1179 -201 0.98 119.64 0.77 0.94 1 978 
-1155 -1140 1 7.51 0.06 0.78 1 15 
-1155 -1138 1 1.26 0 0.21 1 17 
-1155 -1121 0.75 0.43 0.01 0.08 0.97 34 
-1155 -964 0.93 13.64 0.12 0.79 0.98 191 
-1155 -762 0.93 13.6 0.12 0.79 0.98 393 
-1155 -716 0.97 15.28 0.13 0.84 1 439 
-1155 -689 0.97 15.25 0.12 0.84 1 466 
-1155 -666 0.94 14.57 0.12 0.8 0.98 489 
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-1155 -633 0.97 15.58 0.13 0.84 1 522 
-1155 -536 1 0.38 0 0.07 0.98 619 
-1155 -509 1 0.88 0 0.13 0.99 646 
-1155 -486 0.97 14.81 0.12 0.83 1 669 
-1155 -477 0.92 10.68 0.09 0.75 0.98 678 
-1155 -400 1 1.3 0 0.22 1 755 
-1155 -391 1 1.35 0 0.23 1 764 
-1155 -369 1 13.4 0.11 0.87 1 786 
-1155 -201 1 16.4 0.13 0.89 1 954 
-1140 -1138 0.65 0.72 0.01 0.11 0.9 2 
-1140 -1121 1 6.72 0.05 0.76 1 19 
-1140 -964 0.99 95.7 0.65 0.96 1 176 
-1140 -762 0.91 77.37 0.56 0.86 0.95 378 
-1140 -716 0.92 80.57 0.58 0.87 0.96 424 
-1140 -689 0.92 80.09 0.57 0.87 0.96 451 
-1140 -666 0.89 77.2 0.56 0.84 0.94 474 
-1140 -633 0.91 80.11 0.58 0.86 0.95 507 
-1140 -536 1 3.06 0.01 0.54 1 604 
-1140 -509 1 1.36 0.02 0.23 1 631 
-1140 -486 0.92 78.74 0.56 0.86 0.96 654 
-1140 -477 0.91 65.54 0.48 0.85 0.95 663 
-1140 -400 1 0.8 0.02 0.13 0.98 740 
-1140 -391 1 1.01 0.02 0.17 0.99 749 
-1140 -369 0.93 69.41 0.5 0.87 0.97 771 
-1140 -201 0.91 76.5 0.57 0.86 0.95 939 
-1138 -1121 1 0.67 0 0.1 0.99 17 
-1138 -964 0.84 2.18 0.02 0.37 0.96 174 
-1138 -762 0.82 1.92 0.02 0.33 0.95 376 
-1138 -716 0.83 2.09 0.02 0.36 0.95 422 
-1138 -689 0.83 2.09 0.02 0.36 0.95 449 
-1138 -666 0.82 1.9 0.02 0.33 0.95 472 
-1138 -633 0.83 2 0.02 0.34 0.95 505 
-1138 -536 0.7 0.04 0 0.04 0.96 602 
-1138 -509 0.87 25.88 0.59 0.73 0.95 629 
-1138 -486 0.84 2.17 0.02 0.37 0.95 652 
-1138 -477 1 6.82 0.04 0.76 1 661 
-1138 -400 0.93 37.84 0.79 0.83 0.98 738 
-1138 -391 0.93 38.88 0.8 0.83 0.98 747 
-1138 -369 1 6.79 0.04 0.76 1 769 
-1138 -201 0.83 2 0.02 0.35 0.95 937 
-1121 -964 1 9.35 0.08 0.82 1 157 
-1121 -762 1 9.03 0.08 0.82 1 359 
-1121 -716 1 8.82 0.08 0.81 1 405 
-1121 -689 1 8.53 0.08 0.81 1 432 
-1121 -666 1 8.02 0.07 0.8 1 455 
-1121 -633 1 8.3 0.07 0.8 1 488 
-1121 -536 1 0.51 0 0.08 0.98 585 
-1121 -509 1 0.66 0 0.1 0.99 612 
-1121 -486 1 8.8 0.08 0.81 1 635 
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-1121 -477 0.95 9.68 0.08 0.77 0.99 644 
-1121 -400 1 0.71 0 0.11 0.99 721 
-1121 -391 1 0.75 0 0.11 0.99 730 
-1121 -369 0.95 9.75 0.08 0.77 0.99 752 
-1121 -201 1 8.38 0.08 0.8 1 920 
-964 -762 0.95 134.38 0.87 0.92 0.98 202 
-964 -716 0.96 139.48 0.89 0.92 0.98 248 
-964 -689 0.95 137.33 0.88 0.91 0.97 275 
-964 -666 0.97 137.79 0.88 0.93 0.99 298 
-964 -633 0.97 142.93 0.9 0.94 0.99 331 
-964 -536 1 3.72 0.02 0.6 1 428 
-964 -509 1 2.69 0.03 0.48 1 455 
-964 -486 0.93 132.51 0.86 0.9 0.96 478 
-964 -477 0.91 102.72 0.73 0.87 0.95 487 
-964 -400 1 2.83 0.04 0.5 1 564 
-964 -391 1 3.12 0.04 0.53 1 573 
-964 -369 0.94 110.39 0.77 0.9 0.97 595 
-964 -201 0.96 136.68 0.89 0.93 0.99 763 
-762 -716 0.99 190.14 0.98 0.97 1 46 
-762 -689 0.99 189.84 0.98 0.97 1 73 
-762 -666 0.99 179.29 0.95 0.97 1 96 
-762 -633 1 190.77 0.99 0.98 1 129 
-762 -536 0.87 2.88 0.02 0.46 0.96 226 
-762 -509 1 3.55 0.03 0.58 1 253 
-762 -486 0.99 175.75 0.95 0.96 1 276 
-762 -477 0.99 140.88 0.82 0.96 1 285 
-762 -400 1 3.92 0.04 0.61 1 362 
-762 -391 1 4.17 0.04 0.63 1 371 
-762 -369 0.99 141.86 0.83 0.96 1 393 
-762 -201 0.99 180.59 0.97 0.97 1 561 
-716 -689 1 196.68 0.99 0.98 1 27 
-716 -666 0.99 181.13 0.96 0.97 1 50 
-716 -633 1 195.16 0.99 0.98 1 83 
-716 -536 1 4.43 0.02 0.65 1 180 
-716 -509 1 3.48 0.03 0.57 1 207 
-716 -486 1 185.31 0.97 0.97 1 230 
-716 -477 0.99 144.85 0.83 0.97 1 239 
-716 -400 1 3.86 0.04 0.61 1 316 
-716 -391 1 4.35 0.04 0.65 1 325 
-716 -369 1 148.3 0.84 0.98 1 347 
-716 -201 0.99 186.52 0.98 0.97 1 515 
-689 -666 1 183.85 0.96 0.97 1 23 
-689 -633 1 194 0.99 0.98 1 56 
-689 -536 1 4.43 0.02 0.65 1 153 
-689 -509 1 3.48 0.03 0.57 1 180 
-689 -486 0.99 183.41 0.96 0.97 1 203 
-689 -477 0.99 146.15 0.83 0.97 1 212 
-689 -400 1 3.86 0.04 0.61 1 289 
-689 -391 1 4.36 0.04 0.65 1 298 
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-689 -369 1 148.3 0.84 0.98 1 320 
-689 -201 0.99 186.52 0.98 0.97 1 488 
-666 -633 0.99 187.77 0.98 0.97 1 33 
-666 -536 1 4.3 0.02 0.64 1 130 
-666 -509 1 3.32 0.03 0.56 1 157 
-666 -486 1 182.33 0.96 0.98 1 180 
-666 -477 0.99 140.81 0.81 0.97 1 189 
-666 -400 1 3.64 0.04 0.59 1 266 
-666 -391 1 4.13 0.04 0.63 1 275 
-666 -369 1 145.9 0.83 0.98 1 297 
-666 -201 1 181.21 0.97 0.97 1 465 
-633 -536 1 4.36 0.02 0.65 1 97 
-633 -509 1 3.39 0.03 0.56 1 124 
-633 -486 1 180.99 0.96 0.97 1 147 
-633 -477 1 145.48 0.83 0.98 1 156 
-633 -400 1 3.74 0.04 0.6 1 233 
-633 -391 1 4.27 0.04 0.64 1 242 
-633 -369 1 146.98 0.84 0.98 1 264 
-633 -201 1 184.32 0.98 0.97 1 432 
-536 -509 0.03 0.07 0 -0.01 0.2 27 
-536 -486 1 4.53 0.02 0.66 1 50 
-536 -477 0.87 3.09 0.02 0.48 0.97 59 
-536 -400 0.01 0 0 -0.01 0.2 136 
-536 -391 0.05 0.12 0 0 0.23 145 
-536 -369 1 4.44 0.03 0.65 1 167 
-536 -201 1 4.52 0.02 0.66 1 335 
-509 -486 1 3.57 0.03 0.58 1 23 
-509 -477 1 4.62 0.03 0.66 1 32 
-509 -400 0.92 30.14 0.63 0.79 0.98 109 
-509 -391 0.96 32.44 0.67 0.84 1 118 
-509 -369 1 4.55 0.03 0.66 1 140 
-509 -201 1 3.89 0.03 0.61 1 308 
-486 -477 0.98 142.52 0.83 0.95 1 9 
-486 -400 1 3.96 0.04 0.62 1 86 
-486 -391 1 4.46 0.04 0.65 1 95 
-486 -369 0.99 147.59 0.85 0.97 1 117 
-486 -201 0.98 176.32 0.96 0.96 1 285 
-477 -400 1 6.86 0.04 0.76 1 77 
-477 -391 1 7.16 0.04 0.77 1 86 
-477 -369 1 197.39 1 0.99 1 108 
-477 -201 0.99 139.56 0.82 0.96 1 276 
-400 -391 0.97 51.84 0.94 0.9 1 9 
-400 -369 1 6.8 0.04 0.76 1 31 
-400 -201 1 4.03 0.04 0.62 1 199 
-391 -369 1 7.11 0.04 0.77 1 22 
-391 -201 1 4.28 0.04 0.64 1 190 
-369 -201 0.99 141.34 0.83 0.96 1 168 
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APPENDIX J 
HAPLOVIEW DATA: CASES 
J.1  
SNP Position ObsHET PredHET HWpval %Geno Minor AF 
-1305 0.471 0.497 0.314 94.2 0.459 
-1179 0.454 0.5 0.068 93.3 0.49 
-1155 0.186 0.18 0.743 94.2 0.1 
-1140 0.436 0.461 0.304 93.6 0.36 
-1138 0.069 0.075 0.251 93.6 0.039 
-1121 0.16 0.151 0.394 94 0.083 
-964 0.462 0.497 0.194 88.7 0.459 
-762 0.477 0.496 0.46 98 0.458 
-716 0.481 0.496 0.57 99.1 0.455 
-689 0.483 0.496 0.636 99.6 0.455 
-666 0.469 0.494 0.302 98.9 0.447 
-646 0.033 0.033 1 99.8 0.017 
-633 0.468 0.495 0.284 98 0.451 
-543 0.04 0.04 1 98.9 0.02 
-536 0.052 0.05 1 98.9 0.026 
-509 0.056 0.059 0.668 98.7 0.03 
-486 0.473 0.497 0.349 98.4 0.459 
-477 0.458 0.5 0.091 97.8 0.497 
-400 0.074 0.08 0.336 98.9 0.041 
-391 0.078 0.083 0.397 99.1 0.044 
-369 0.455 0.5 0.071 96 0.495 
-201 0.476 0.497 0.411 96 0.462 
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J.2  
L1 L2 D' LOD r^2 CI low Chi Distance 
-1305 -1179 1 71.68 0.8 0.97 1 126 
-1305 -1155 1 9.48 0.13 0.82 1 150 
-1305 -1140 0.99 50.21 0.6 0.93 1 165 
-1305 -1138 1 3.28 0.05 0.55 1 167 
-1305 -1121 1 6.54 0.09 0.75 1 184 
-1305 -964 0.98 91.9 0.96 0.95 1 341 
-1305 -762 0.94 75.67 0.87 0.9 0.98 543 
-1305 -716 0.96 79.47 0.88 0.92 0.99 589 
-1305 -689 0.96 79.19 0.88 0.92 0.99 616 
-1305 -666 0.96 79.19 0.88 0.92 0.99 639 
-1305 -633 0.96 78.14 0.87 0.92 0.99 672 
-1305 -536 1 1.9 0.02 0.34 1 769 
-1305 -509 1 1.98 0.04 0.36 1 796 
-1305 -486 0.93 76.77 0.87 0.89 0.97 819 
-1305 -477 0.92 57.87 0.72 0.85 0.96 828 
-1305 -400 1 2.44 0.05 0.44 1 905 
-1305 -391 1 2.73 0.05 0.49 1 914 
-1305 -369 0.92 57.87 0.72 0.85 0.96 936 
-1305 -201 0.95 76.22 0.87 0.9 0.98 1104 
-1179 -1155 1 7.18 0.11 0.77 1 24 
-1179 -1140 1 42.94 0.51 0.95 1 39 
-1179 -1138 1 3.71 0.04 0.6 1 41 
-1179 -1121 0.85 4.95 0.08 0.57 0.95 58 
-1179 -964 0.99 67.54 0.78 0.94 1 215 
-1179 -762 0.97 59.94 0.73 0.91 0.99 417 
-1179 -716 0.99 63.54 0.74 0.94 1 463 
-1179 -689 0.99 63.3 0.74 0.94 1 490 
-1179 -666 0.99 63.3 0.74 0.94 1 513 
-1179 -633 0.99 62.75 0.73 0.94 1 546 
-1179 -536 1 2.04 0.03 0.37 1 643 
-1179 -509 1 2.39 0.03 0.43 1 670 
-1179 -486 0.96 59.44 0.72 0.9 0.99 693 
-1179 -477 0.96 78.59 0.88 0.92 0.99 702 
-1179 -400 1 3.7 0.04 0.59 1 779 
-1179 -391 1 3.68 0.04 0.59 1 788 
-1179 -369 0.96 78.59 0.88 0.92 0.99 810 
-1179 -201 0.98 61.29 0.73 0.93 1 978 
-1155 -1140 1 4.74 0.08 0.67 1 15 
-1155 -1138 1 0.85 0.01 0.13 0.99 17 
-1155 -1121 0.79 0.28 0.01 0.06 0.97 34 
-1155 -964 0.94 7.56 0.12 0.72 0.99 191 
-1155 -762 1 9.51 0.13 0.82 1 393 
-1155 -716 1 9.85 0.14 0.83 1 439 
-1155 -689 1 9.86 0.14 0.83 1 466 
-1155 -666 1 9.86 0.14 0.83 1 489 
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-1155 -633 1 9.98 0.14 0.83 1 522 
-1155 -536 1 0.24 0 0.05 0.97 619 
-1155 -509 1 0.52 0 0.08 0.98 646 
-1155 -486 1 9.4 0.13 0.82 1 669 
-1155 -477 1 7.4 0.11 0.78 1 678 
-1155 -400 1 0.86 0.01 0.13 0.99 755 
-1155 -391 1 0.91 0.01 0.14 0.99 764 
-1155 -369 1 7.4 0.11 0.78 1 786 
-1155 -201 1 9.76 0.14 0.83 1 954 
-1140 -1138 1 1.54 0.03 0.27 1 2 
-1140 -1121 1 4.32 0.06 0.64 1 19 
-1140 -964 0.99 50.03 0.61 0.93 1 176 
-1140 -762 0.89 37.83 0.52 0.81 0.95 378 
-1140 -716 0.9 39.36 0.53 0.82 0.95 424 
-1140 -689 0.9 39.17 0.53 0.82 0.95 451 
-1140 -666 0.9 39.17 0.53 0.82 0.95 474 
-1140 -633 0.88 38.22 0.52 0.8 0.94 507 
-1140 -536 1 1.34 0.01 0.22 1 604 
-1140 -509 1 0.83 0.02 0.13 0.99 631 
-1140 -486 0.91 39.64 0.52 0.83 0.96 654 
-1140 -477 0.91 33.16 0.44 0.82 0.96 663 
-1140 -400 1 0.7 0.03 0.11 0.99 740 
-1140 -391 1 0.89 0.03 0.14 0.99 749 
-1140 -369 0.91 33.16 0.44 0.82 0.96 771 
-1140 -201 0.88 37.57 0.51 0.8 0.94 939 
-1138 -1121 1 0.22 0 0.05 0.97 17 
-1138 -964 1 3.24 0.05 0.55 1 174 
-1138 -762 1 2.53 0.05 0.46 1 376 
-1138 -716 1 2.72 0.05 0.48 1 422 
-1138 -689 1 2.72 0.05 0.48 1 449 
-1138 -666 1 2.72 0.05 0.48 1 472 
-1138 -633 1 2.68 0.05 0.48 1 505 
-1138 -536 0.03 0.01 0 0 0.34 602 
-1138 -509 0.86 14.23 0.55 0.66 0.95 629 
-1138 -486 1 2.9 0.05 0.51 1 652 
-1138 -477 1 3.94 0.04 0.62 1 661 
-1138 -400 0.94 22.92 0.8 0.8 0.99 738 
-1138 -391 0.95 23.92 0.81 0.81 0.99 747 
-1138 -369 1 3.94 0.04 0.62 1 769 
-1138 -201 1 2.45 0.05 0.44 1 937 
-1121 -964 1 6.17 0.09 0.74 1 157 
-1121 -762 1 5.7 0.09 0.72 1 359 
-1121 -716 1 5.46 0.09 0.71 1 405 
-1121 -689 1 5.46 0.09 0.71 1 432 
-1121 -666 1 5.46 0.09 0.71 1 455 
-1121 -633 1 5.38 0.09 0.71 1 488 
-1121 -536 1 0.39 0 0.06 0.98 585 
-1121 -509 1 0.28 0 0.06 0.98 612 
-1121 -486 1 5.78 0.09 0.73 1 635 
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-1121 -477 0.92 5.9 0.09 0.66 0.98 644 
-1121 -400 1 0.22 0 0.05 0.97 721 
-1121 -391 1 0.26 0 0.06 0.97 730 
-1121 -369 0.92 5.9 0.09 0.66 0.98 752 
-1121 -201 1 5.54 0.09 0.72 1 920 
-964 -762 0.94 72.92 0.85 0.89 0.97 202 
-964 -716 0.96 76.68 0.87 0.92 0.99 248 
-964 -689 0.96 76.41 0.87 0.92 0.99 275 
-964 -666 0.96 76.41 0.87 0.92 0.99 298 
-964 -633 0.96 75.4 0.86 0.91 0.99 331 
-964 -536 1 1.89 0.02 0.34 1 428 
-964 -509 1 1.96 0.04 0.35 1 455 
-964 -486 0.93 73.97 0.85 0.88 0.97 478 
-964 -477 0.91 56.31 0.71 0.85 0.96 487 
-964 -400 1 2.43 0.05 0.44 1 564 
-964 -391 1 2.71 0.05 0.49 1 573 
-964 -369 0.91 56.31 0.71 0.85 0.96 595 
-964 -201 0.96 74.84 0.86 0.91 0.99 763 
-762 -716 1 103.96 0.98 0.98 1 46 
-762 -689 1 103.66 0.98 0.98 1 73 
-762 -666 1 103.66 0.98 0.98 1 96 
-762 -633 1 101.98 0.97 0.97 1 129 
-762 -536 0.72 0.88 0.01 0.14 0.92 226 
-762 -509 1 2.26 0.04 0.41 1 253 
-762 -486 0.98 95.82 0.95 0.95 1 276 
-762 -477 0.98 72.05 0.78 0.93 1 285 
-762 -400 1 2.97 0.05 0.52 1 362 
-762 -391 1 3.25 0.05 0.55 1 371 
-762 -369 0.98 73.14 0.8 0.93 1 393 
-762 -201 0.99 99.5 0.97 0.96 1 561 
-716 -689 1 109.23 1 0.98 1 27 
-716 -666 1 109.23 1 0.98 1 50 
-716 -633 1 106.72 0.99 0.98 1 83 
-716 -536 1 2.1 0.02 0.38 1 180 
-716 -509 1 2.17 0.04 0.39 1 207 
-716 -486 1 101.36 0.97 0.97 1 230 
-716 -477 1 76.89 0.8 0.97 1 239 
-716 -400 1 2.88 0.05 0.51 1 316 
-716 -391 1 3.42 0.06 0.57 1 325 
-716 -369 1 77.56 0.81 0.97 1 347 
-716 -201 0.99 103.65 0.98 0.96 1 515 
-689 -666 1 109.23 1 0.98 1 23 
-689 -633 1 106.42 0.99 0.98 1 56 
-689 -536 1 2.1 0.02 0.38 1 153 
-689 -509 1 2.17 0.04 0.39 1 180 
-689 -486 1 101.07 0.97 0.97 1 203 
-689 -477 1 76.89 0.8 0.97 1 212 
-689 -400 1 2.88 0.05 0.51 1 289 
-689 -391 1 3.42 0.06 0.57 1 298 
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-689 -369 1 77.31 0.81 0.97 1 320 
-689 -201 0.99 103.35 0.98 0.96 1 488 
-666 -633 1 106.42 0.99 0.98 1 33 
-666 -536 1 2.1 0.02 0.38 1 130 
-666 -509 1 2.17 0.04 0.39 1 157 
-666 -486 1 101.07 0.97 0.97 1 180 
-666 -477 1 76.89 0.8 0.97 1 189 
-666 -400 1 2.88 0.05 0.51 1 266 
-666 -391 1 3.42 0.06 0.57 1 275 
-666 -369 1 77.31 0.81 0.97 1 297 
-666 -201 0.99 103.35 0.98 0.96 1 465 
-633 -536 1 2.08 0.02 0.38 1 97 
-633 -509 1 2.14 0.04 0.39 1 124 
-633 -486 1 99.65 0.96 0.97 1 147 
-633 -477 1 75.98 0.8 0.97 1 156 
-633 -400 1 2.84 0.05 0.5 1 233 
-633 -391 1 3.38 0.05 0.57 1 242 
-633 -369 1 76.63 0.8 0.97 1 264 
-633 -201 0.99 101.75 0.97 0.96 1 432 
-536 -509 0.03 0.03 0 0 0.32 27 
-536 -486 1 2.19 0.02 0.4 1 50 
-536 -477 1 2.02 0.03 0.36 1 59 
-536 -400 0 0 0 0.03 0.96 136 
-536 -391 0.09 0.14 0 0 0.37 145 
-536 -369 1 1.97 0.02 0.35 1 167 
-536 -201 1 2.1 0.02 0.38 1 335 
-509 -486 1 2.28 0.03 0.41 1 23 
-509 -477 1 2.75 0.03 0.49 1 32 
-509 -400 0.87 15.03 0.54 0.67 0.96 109 
-509 -391 0.93 17.03 0.6 0.75 0.99 118 
-509 -369 1 2.81 0.03 0.5 1 140 
-509 -201 1 2.5 0.04 0.45 1 308 
-486 -477 0.99 76.87 0.81 0.95 1 9 
-486 -400 1 3.07 0.05 0.53 1 86 
-486 -391 1 3.62 0.06 0.59 1 95 
-486 -369 0.99 77.58 0.82 0.95 1 117 
-486 -201 0.99 98.01 0.96 0.96 1 285 
-477 -400 1 4.08 0.04 0.63 1 77 
-477 -391 1 4.38 0.04 0.65 1 86 
-477 -369 1 109.16 1 0.98 1 108 
-477 -201 0.99 73.57 0.79 0.95 1 276 
-400 -391 0.95 29.38 0.91 0.85 0.99 9 
-400 -369 1 4.12 0.04 0.63 1 31 
-400 -201 1 2.88 0.05 0.51 1 199 
-391 -369 1 4.4 0.04 0.65 1 22 
-391 -201 1 3.15 0.05 0.54 1 190 
-369 -201 0.99 74.63 0.8 0.95 1 168 
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APPENDIX K 
HAPLOVIEW DATA: CONTROLS 
K.1  
SNP Position ObsHET PredHET HWpval %Geno Minor AF 
-1305 0.505 0.485 0.677 94.5 0.413 
-1179 0.493 0.496 0.996 93.1 0.458 
-1155 0.157 0.153 1 93.6 0.083 
-1140 0.443 0.446 1 93.1 0.335 
-1138 0.059 0.058 1 92.7 0.03 
-1121 0.153 0.149 1 93.1 0.081 
-964 0.495 0.484 0.914 84.4 0.41 
-762 0.519 0.486 0.42 96.3 0.417 
-716 0.528 0.487 0.284 98.2 0.418 
-689 0.535 0.487 0.205 99.5 0.419 
-666 0.505 0.481 0.582 98.2 0.402 
-646 0.032 0.032 1 99.5 0.016 
-633 0.51 0.484 0.568 96.3 0.412 
-543 0.028 0.028 1 98.6 0.014 
-536 0.056 0.054 1 98.6 0.028 
-509 0.051 0.05 1 98.6 0.026 
-486 0.524 0.486 0.348 97.2 0.417 
-477 0.528 0.496 0.43 97.2 0.453 
-400 0.065 0.063 1 99.1 0.032 
-391 0.065 0.063 1 98.6 0.033 
-369 0.525 0.496 0.512 93.6 0.453 
-201 0.53 0.49 0.325 92.7 0.428 
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K.2  
L1 L2 D' LOD r^2 CI low Chi Dist 
-1305 -1179 1 64.63 0.83 0.96 1 126 
-1305 -1155 1 7.78 0.13 0.79 1 150 
-1305 -1140 0.92 39.7 0.62 0.84 0.96 165 
-1305 -1138 0.44 0.17 0 0.04 0.86 167 
-1305 -1121 1 3.8 0.06 0.6 1 184 
-1305 -964 0.99 71.92 0.96 0.95 1 341 
-1305 -762 0.94 63.42 0.87 0.89 0.97 543 
-1305 -716 0.95 65.14 0.87 0.9 0.98 589 
-1305 -689 0.95 63.78 0.85 0.9 0.98 616 
-1305 -666 0.94 62.59 0.85 0.88 0.97 639 
-1305 -633 0.96 69.28 0.91 0.91 0.99 672 
-1305 -536 1 2 0.02 0.36 1 769 
-1305 -509 1 1.17 0.02 0.19 0.99 796 
-1305 -486 0.94 60.94 0.84 0.88 0.97 819 
-1305 -477 0.92 48.65 0.72 0.85 0.96 828 
-1305 -400 1 0.98 0.02 0.15 0.99 905 
-1305 -391 1 1 0.02 0.16 0.99 914 
-1305 -369 0.98 57.19 0.81 0.92 1 936 
-1305 -201 0.97 64.75 0.89 0.92 0.99 1104 
-1179 -1155 1 6.11 0.11 0.74 1 24 
-1179 -1140 0.98 41.21 0.59 0.92 1 39 
-1179 -1138 1 2.67 0.03 0.47 1 41 
-1179 -1121 1 4.42 0.08 0.65 1 58 
-1179 -964 1 62.88 0.87 0.96 1 215 
-1179 -762 0.98 56.84 0.79 0.92 1 417 
-1179 -716 0.97 57.58 0.79 0.91 0.99 463 
-1179 -689 0.94 55.61 0.77 0.89 0.98 490 
-1179 -666 0.99 57.96 0.78 0.94 1 513 
-1179 -633 1 63.36 0.83 0.96 1 546 
-1179 -536 1 2.1 0.02 0.38 1 643 
-1179 -509 1 1.58 0.03 0.27 1 670 
-1179 -486 0.94 54.34 0.77 0.88 0.98 693 
-1179 -477 0.95 64.39 0.86 0.9 0.98 702 
-1179 -400 1 2.36 0.04 0.42 1 779 
-1179 -391 1 2.34 0.04 0.42 1 788 
-1179 -369 1 77.14 0.96 0.97 1 810 
-1179 -201 0.98 58.19 0.83 0.92 1 978 
-1155 -1140 1 3.07 0.05 0.53 1 15 
-1155 -1138 1 0.47 0 0.07 0.98 17 
-1155 -1121 0.71 0.15 0 0.05 0.97 34 
-1155 -964 0.92 5.75 0.12 0.66 0.98 191 
-1155 -762 0.84 4.45 0.09 0.55 0.95 393 
-1155 -716 0.92 5.45 0.11 0.65 0.98 439 
-1155 -689 0.92 5.4 0.11 0.64 0.98 466 
-1155 -666 0.85 4.97 0.1 0.57 0.95 489 
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-1155 -633 0.92 5.59 0.11 0.65 0.98 522 
-1155 -536 1 0.13 0 0.05 0.97 619 
-1155 -509 1 0.39 0 0.06 0.98 646 
-1155 -486 0.92 5.37 0.11 0.64 0.98 669 
-1155 -477 0.82 3.51 0.07 0.48 0.94 678 
-1155 -400 1 0.5 0 0.08 0.98 755 
-1155 -391 1 0.51 0 0.08 0.98 764 
-1155 -369 1 5.51 0.1 0.71 1 786 
-1155 -201 1 6.31 0.11 0.74 1 954 
-1140 -1138 0.01 0 0 0.02 0.8 2 
-1140 -1121 1 2.46 0.04 0.44 1 19 
-1140 -964 1 45.34 0.69 0.95 1 176 
-1140 -762 0.93 39.47 0.62 0.85 0.97 378 
-1140 -716 0.94 41.23 0.63 0.87 0.98 424 
-1140 -689 0.94 40.86 0.62 0.87 0.98 451 
-1140 -666 0.89 37.7 0.6 0.81 0.94 474 
-1140 -633 0.94 42.16 0.65 0.87 0.98 507 
-1140 -536 1 1.68 0.01 0.3 1 604 
-1140 -509 1 0.61 0.01 0.1 0.98 631 
-1140 -486 0.93 38.87 0.61 0.85 0.97 654 
-1140 -477 0.91 32.17 0.52 0.82 0.96 663 
-1140 -400 0.95 0.25 0.02 0.06 0.97 740 
-1140 -391 0.98 0.27 0.02 0.06 0.97 749 
-1140 -369 0.95 36.63 0.58 0.88 0.99 771 
-1140 -201 0.94 39.38 0.64 0.87 0.98 939 
-1138 -1121 1 0.45 0 0.07 0.98 17 
-1138 -964 0.3 0.06 0 0.03 0.84 174 
-1138 -762 0.47 0.2 0.01 0.04 0.87 376 
-1138 -716 0.48 0.21 0.01 0.04 0.87 422 
-1138 -689 0.48 0.21 0.01 0.04 0.87 449 
-1138 -666 0.41 0.13 0 0.04 0.86 472 
-1138 -633 0.45 0.18 0 0.04 0.86 505 
-1138 -536 1 0.15 0 0.04 0.97 602 
-1138 -509 0.9 11.65 0.67 0.66 0.98 629 
-1138 -486 0.47 0.19 0 0.04 0.87 652 
-1138 -477 1 2.71 0.04 0.48 1 661 
-1138 -400 0.91 14.68 0.77 0.72 0.98 738 
-1138 -391 0.91 14.65 0.77 0.72 0.98 747 
-1138 -369 1 2.7 0.04 0.48 1 769 
-1138 -201 0.53 0.27 0.01 0.05 0.88 937 
-1121 -964 1 3.37 0.06 0.56 1 157 
-1121 -762 1 3.41 0.07 0.57 1 359 
-1121 -716 1 3.45 0.07 0.57 1 405 
-1121 -689 1 3.17 0.06 0.54 1 432 
-1121 -666 1 2.68 0.06 0.48 1 455 
-1121 -633 1 3.06 0.06 0.53 1 488 
-1121 -536 1 0.12 0 0.04 0.97 585 
-1121 -509 1 0.38 0 0.06 0.98 612 
-1121 -486 1 3.13 0.07 0.54 1 635 
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-1121 -477 1 4.11 0.08 0.63 1 644 
-1121 -400 1 0.49 0 0.08 0.98 721 
-1121 -391 1 0.49 0 0.08 0.98 730 
-1121 -369 1 4.15 0.08 0.63 1 752 
-1121 -201 1 2.95 0.07 0.52 1 920 
-964 -762 0.96 60.47 0.9 0.91 0.99 202 
-964 -716 0.95 61.91 0.9 0.9 0.98 248 
-964 -689 0.94 60.15 0.88 0.89 0.98 275 
-964 -666 0.98 60.06 0.88 0.93 1 298 
-964 -633 0.99 67.11 0.94 0.95 1 331 
-964 -536 1 1.81 0.02 0.33 1 428 
-964 -509 1 0.92 0.02 0.14 0.99 455 
-964 -486 0.93 57.31 0.86 0.88 0.96 478 
-964 -477 0.91 45.17 0.74 0.84 0.96 487 
-964 -400 1 0.72 0.02 0.11 0.99 564 
-964 -391 1 0.74 0.02 0.11 0.99 573 
-964 -369 0.97 53.85 0.84 0.92 1 595 
-964 -201 0.96 61.68 0.93 0.92 0.99 763 
-762 -716 1 86.32 0.98 0.97 1 46 
-762 -689 1 86.32 0.98 0.97 1 73 
-762 -666 0.98 75.58 0.92 0.94 1 96 
-762 -633 1 88.57 1 0.98 1 129 
-762 -536 1 2.28 0.02 0.42 1 226 
-762 -509 1 1.45 0.02 0.25 1 253 
-762 -486 0.99 78.88 0.95 0.95 1 276 
-762 -477 1 68.42 0.86 0.97 1 285 
-762 -400 1 1.26 0.03 0.21 1 362 
-762 -391 1 1.26 0.03 0.21 1 371 
-762 -369 1 68.3 0.88 0.97 1 393 
-762 -201 0.99 80.54 0.98 0.96 1 561 
-716 -689 0.99 87.11 0.98 0.96 1 27 
-716 -666 0.98 73.97 0.91 0.94 1 50 
-716 -633 1 87.46 0.99 0.98 1 83 
-716 -536 1 2.29 0.02 0.42 1 180 
-716 -509 1 1.46 0.02 0.25 1 207 
-716 -486 0.99 83.34 0.97 0.96 1 230 
-716 -477 0.99 67.29 0.85 0.94 1 239 
-716 -400 1 1.28 0.02 0.21 1 316 
-716 -391 1 1.28 0.02 0.21 1 325 
-716 -369 1 69.81 0.88 0.97 1 347 
-716 -201 0.99 82.12 0.98 0.96 1 515 
-689 -666 0.99 76.31 0.92 0.95 1 23 
-689 -633 1 86.63 0.98 0.97 1 56 
-689 -536 1 2.3 0.02 0.42 1 153 
-689 -509 1 1.47 0.02 0.25 1 180 
-689 -486 0.98 82.04 0.96 0.95 1 203 
-689 -477 0.99 68.76 0.86 0.95 1 212 
-689 -400 1 1.29 0.02 0.21 1 289 
-689 -391 1 1.29 0.02 0.21 1 298 
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-689 -369 1 70.09 0.88 0.97 1 320 
-689 -201 0.99 82.43 0.98 0.96 1 488 
-666 -633 0.99 81.2 0.96 0.95 1 33 
-666 -536 1 2.16 0.02 0.4 1 130 
-666 -509 1 1.34 0.02 0.23 1 157 
-666 -486 1 80.13 0.94 0.97 1 180 
-666 -477 0.99 62.78 0.81 0.94 1 189 
-666 -400 1 1.13 0.02 0.18 0.99 266 
-666 -391 1 1.13 0.02 0.18 0.99 275 
-666 -369 1 67.38 0.86 0.96 1 297 
-666 -201 1 77.98 0.95 0.97 1 465 
-633 -536 1 2.24 0.02 0.41 1 97 
-633 -509 1 1.41 0.02 0.24 1 124 
-633 -486 0.99 80.59 0.96 0.95 1 147 
-633 -477 1 68.62 0.86 0.97 1 156 
-633 -400 1 1.22 0.02 0.2 1 233 
-633 -391 1 1.24 0.02 0.2 1 242 
-633 -369 1 69.53 0.88 0.97 1 264 
-633 -201 1 82.1 0.98 0.97 1 432 
-536 -509 0.04 0.05 0 0 0.29 27 
-536 -486 1 2.31 0.02 0.42 1 50 
-536 -477 0.77 1.28 0.01 0.22 0.94 59 
-536 -400 0.02 0.01 0 -0.01 0.26 136 
-536 -391 0.02 0.01 0 -0.01 0.26 145 
-536 -369 1 2.33 0.03 0.42 1 167 
-536 -201 1 2.37 0.02 0.43 1 335 
-509 -486 1 1.44 0.02 0.25 1 23 
-509 -477 1 1.75 0.03 0.31 1 32 
-509 -400 1 15.76 0.78 0.81 1 109 
-509 -391 1 15.74 0.78 0.81 1 118 
-509 -369 1 1.73 0.03 0.31 1 140 
-509 -201 1 1.52 0.02 0.26 1 308 
-486 -477 0.98 64.29 0.83 0.93 1 9 
-486 -400 1 1.25 0.02 0.21 1 86 
-486 -391 1 1.25 0.02 0.21 1 95 
-486 -369 1 68.97 0.88 0.97 1 117 
-486 -201 0.99 77.96 0.96 0.95 1 285 
-477 -400 1 2.53 0.04 0.45 1 77 
-477 -391 1 2.53 0.04 0.45 1 86 
-477 -369 1 86.91 0.99 0.98 1 108 
-477 -201 0.99 65.37 0.86 0.94 1 276 
-400 -391 1 22.59 1 0.89 1 9 
-400 -369 1 2.53 0.04 0.45 1 31 
-400 -201 1 1.42 0.02 0.24 1 199 
-391 -369 1 2.53 0.04 0.45 1 22 
-391 -201 1 1.42 0.02 0.24 1 190 
-369 -201 0.99 66.05 0.87 0.94 1 168 
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